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INTRODUCTION 
With increasing consumption of alcohol and increasing burden of 
chronic liver disease patients in India and across the world, research efforts 
have only managed to raise more questions than provide answers to the 
demands of both logic, science and clinicosocial burden of patients with this 
disease. With more definitive and curative treatments becoming available 
for liver diseases due to viral etiologies and intermediary metabolites, it is 
alcoholic liver disease that seems to have been orphaned with respect to 
finding cures and clear potential targets in the pathological process. 
Counterintuitive to that which may be believed, perhaps more 
breakthroughs are achieved by finding cures by trial and error and then 
subsequently managing to elucidate the exact reason for its curative 
potential, which may thus give rise to a subsequent breakthrough in the 
pathophysiology of the inciting process. Betaine is a drug that acts as a 
methyl group donor whereby it reduces the fatty burden and interrupts the 
pathogenic process in non alcoholic fatty liver disease. Its use has yet to be 
explored on alcoholic liver disease. It must also be impressed that it is in no 
way a random choice of drug as multiple trials have been done in the past 
but with other diseases and this particular scenario has perhaps not been 
satisfactorily subjected to the potential of betaine. No evidence has emerged 
theoretically precluding the utility of this drug in the above scenario. It is 
with this inquisitiveness that this possibility is being explored. 
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AIMS AND OBJECTIVES 
 
- To study the “BETAINE THERAPY AND ITS INFLUENCE ON 
OUTCOME OF ACUTE ON CHRONIC ALCOHOLIC LIVER 
DISEASE’’ 
 
 
  
  
 
REVIEW  
OF  
LITERATURE 
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ALCOHOLIC LIVER DISEASE 
 Alcoholic liver disease (ALD) is a major cause of chronic liver 
disease worldwide and can lead to fibrosis and cirrhosis. Forty eight percent 
of all cirrhosis related deaths are alcohol related (2011). The spectrum of 
disease ranges from fatty liver, alcoholic hepatitis which leads to fibrosis, 
cirrhosis, and finally to hepatocellular carcinoma 
RISK FACTORS 
Younger age of initiation of the alcohol habit has shown to be a risk 
factor for development of alcoholic liver disease. Female sex is a strong risk 
factor due to increased ratio of body fat and high oestrogen levels. Obesity 
is a separate risk factor which escalates fibrosis progression and the 
development of cirrhosis in ALD. Experiments show that the synergistic 
effects of obesity and alcohol abuse involve the smooth endoplasmic 
reticulum response to cell stress, stimulation or macrophages and end organ 
resistance to adiponectin. Daily Drinking as compared to binge drinking or 
sporadic drinking is associated with a higher incidence of liver disease. 
Smoking is an independent risk factor. Genetic factors also play a role 
especially PNPLA3 mutations. Variations in patatin-like phospholipase 
domain-containing protein 3 (PNPLA3) are associated with liver disease in 
whites.Reduced amount of alcohol dehydrogenase enzyme in the stomach 
mostly seen in female patients is an important risk factor. 
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FIGURE 1  
 
 
Prolonged alcohol drinking has synergistic effects with Hepatitis 
virus B or C and HIV infection, nonalcoholic fatty liver disease, and 
hemochromatosis to accelerate progression of liver diseases. For example, 
many patients with viral hepatitis consume alcohol, which escalates 
progression of liver disease. 
PATHOGENESIS 
Steatosis: Fatty change, the preliminary reaction of the liver to 
alcohol abuse, is typified by the increased presence of lipids (mainly 
triglycerides, phospholipids, and cholesteryl esters) in liver cells. 
Preliminary studies suggested that ethanol intake increases the proportion of 
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reduced nicotinamide adenine dinucleotide/oxidized nicotinamide adenine 
di-nucleotide in liver cells, which inhibits mitochondrial β-oxidation of fatty 
acids and results in fatty change. Ethanol consumption has also been found 
to enhance the transport of fats to the liverliver from the small intestine, 
increasing mobilization of fatty acids from adipose tissue and uptake of fatty 
acids by the liver. However, the contribution of these mechanisms to the 
development of steatosis after long-term alcohol consumption is not clear 
and requires further investigation. 
Liver from the gut, enhancing movement of fatty acids from adipose 
tissue. However, the importance of these events in the context of fatty 
change after chronic ethanol intake is uncertain and mandates subsequent 
research. 
 Recent studies show that alcohol exposure, alters lipid metabolism-
associated transcription factors. This stimulates lipogenesis and inhibits 
fatty acid oxidation. Thus alcohol increases fatty acid synthesis in 
hepatocytes via up-regulation of sterol regulatory element-binding protein 
1c (SREBP-1c), a molecule that stimulates fatty acid synthesis via up-
regulation of lipid forming genes. Alcohol consumption increases 
transcription of SREBP-1c gene via its metabolite acetaldehyde directly or 
by activating pathways and molecules that up-regulate its expression, such 
as the endoplasmic reticular stress reaction and Toll like receptor 4. Alcohol 
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may also decrease factors that reduce SREBP-1c expression, such as AMP-
activated protein kinase (AMPK), and adiponectin. Blockade of SREBP-1c 
in animal models reduced alcohol related fatty change. 
FIGURE 2 
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Alcohol intake decreases fatty acid oxidation in liver parenchyma 
through inactivation of the peroxisome proliferator-activated receptor 
(PPAR)-α, a nuclear hormone receptor. Ethanaldehyde, but not ethyl alcohol 
by itself, directly inhibits the functionality of PPAR-α in liver cells. 
Alcohol intake can also indirectly inhibit PPAR-α via up-regulation 
of cytochrome P2E1-derived free radical stress and adenosine, thereby 
inhibiting PPAR-α, or reducing zinc and adiponectin, which stimulate 
PPAR-α. Alcohol may also cause changes in function of enzymes involved 
in fat metabolism by inhibiting AMPK, which reduces fat metabolism and 
fatty liver. AMPK acts as a serine-threonine kinase that inactivates acetyl-
CoA carboxylase (ACC). Being a rate limiting step of fatty acid synthesis, 
its inactivation is crucial. This also results in reduced levels of malonyl-
CoA, a reactant in the fatty acid synthesis cascade which blocks carnitine 
palmitoyltransferase 1, a rate-limiting step in the fatty acid oxidation 
pathway. 
AMPK through its phosphorylating activity inhibits SREBP activity 
in liver cells, decreasing fatty change. Thus AMPK would normally inhibit 
lipogenesis and up-regulate fatty acid oxidation by inactivating ACCEthanol 
intake blunts AMPK activity in the hepatocytes, causing unchecked 
functioning of ACC and carnitine palmitoyltransferase 1, all of which have 
a crucial role in ALD. Alcohol related fatty change is markedly diminished 
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in many strains of knockout mice with   including HIF-1 and iNOS 
enlightening us of the possible gene interactions which contributes to the 
pathogenesis of alcoholic fatty liver. The possible implications to research 
outcomes are exhilerating. 
Phagocytosis plays an undeniable role in scavenging out fat globules 
in liver cells. Chronic ethanol intake blunts this autophagy response.  
Although short-term alcohol intake stimulates phagocytosis by creating free 
radical species and blocking the mammalian target of rapamycin, suggesting 
that acute alcohol intake could have a balancing act that helps to adjust and 
halt the development of fatty change during the initial insults of alcohol.  
Alcoholic Hepatitis: Alcoholic hepatitis is a syndrome described by 
affection and inflammation of the liver by inflammatory cells leading to 
hepatocellular injury. AH develops in those affected with pre-existing fatty 
change and usually goes on to progressive fibrosis. The prevalence of 
alcoholic hepatitis is not clearly known. Alcoholic hepatitis can range from 
mild injury to severe, life-threatening injury. The histologic characteristics 
of AH include steatosis, centrilobular ballooning of hepatocytes, presence of 
polymorphs, Mallory hyaline inclusions, and a background of ominous 
chicken wire–like fibrotic deposition. Many patients, there may actually be 
underlying cirrhosis.A large body of evidence indicates that many factors 
contribute to alcohol-induced inflammation  
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Toxicity of alcohol: In liver cells, ethanol is metabolized into 
acetaldehyde by alcohol dehydrogenase in the cytoplasm, cytochrome P-450 
in microsomes, (and in perixosomes through catalase ). This creates free 
radical species which results in lipid peroxidation, depletion of glutathione, 
and S-adenosylmethionine insufficiency; which subsequently result in 
hepatocytes to stress and injury. Acetaldehyde is then rapidly metabolized 
into acetic acid-acetate by aldehyde dehydrogenase. Acetaldehyde is a 
reactive compound and it is highly toxic to liver cells because it forms 
dangerous protein changes and DNA adducts that promote lipid 
peroxidation, glutathione depletion, and mitochondrial damage. This acetate 
is immediately released from the liver into the blood stream and  is then 
metabolized into carbon dioxide in the citric acid cycle in other organs 
having a rich mitochondrial content like skeletal and cardiac muscles. 
Acetate admittedly has little direct hepatotoxicity, it is important in the 
inflammation in patients with AH via the resultant stimulation of 
proinflammatory cytokines in macrophages. 
Role of innate immunity: Ethanol intake causes gut dysbiosis and 
bacterial over-growth but also enhances gut permeability and the 
translocation of Lipopolysaccharide from bacteria to the liver. These 
changes explain the increased levels of LPS observed in alcoholic liver 
disease. In Kupffer cells (liver macrophages), LPS binds with TLR4 to 
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activate the MyD88-independent (TRIF/IRF-3) signaling pathway thus 
causing increase of free radical stress and inflammatory molecules, like 
TNF-α, that cause hepatocellular damage. Ethanol intake activates 
complement C3 and C5, which subsequently activate Kupffer cells by 
binding to complement receptors on these cells. This complement activation 
also results In TNF-alpha release. Although activation of TLR4 and 
complement factors do also cause Kupffer cells to produce cytokines such 
as interleukin (IL)-6 and the anti-inflammatory cytokine IL-10, these 
cytokines activate STAT3 in Kupffer cells to protect from alcohol-induced 
liver injury. Thus, the activation of innate immunity components not only 
triggers alcoholic liver injury but also triggers protective responses that 
reduce alcohol-induced hepatocellular damage. 
Liver Cell apoptosis: Hepatocyte apoptosis is an increasingly 
important feature of alcoholic liver disease. Apoptosis results from multiple 
pathways, including direct hepatotoxicity, free radical injury,, and induction 
of proapoptotic molecules (TNF-αand Fas ligand). 
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FIGURE  - 3 
 
 
 
 
12 
 
Role of polymorphs: presence of  polymorphs in the liver parenchyma 
is a stellar feature of AH. Up-regulation of pro-neutrophilic cytokines like 
IL-8, and IL-17 in liver causes this infiltration. Many factors stimulate cells 
to produce these cytokines in patients with AH. These include LPS, 
acetaldehyde, TNF-α,, and blunting of proteasome activities. IL-17, which 
found in high levels in patients with AH, causing polymorph attraction but 
also stimulates sinusoidal stellate cells to produce IL-8 and CXCL1; which 
results in infiltration of the parenchyma with polymorphs. Also, IL-8 and 
CXCL1 are secreted by activated stellate cells and Kupffer cells, which 
promote further neutrophil recruitment. Many other chemokines and 
cytokines are markedly up-regulated promoting infiltration of neutrophils 
during progression of AH. Neutrophil infiltration strongly correlates with 
the severity of AH, but there is no direct evidence in animal experiments to 
ascertain the role of neutrophils in pathogenesis 
Role played by adaptive immunity: Individuals with alcoholic 
hepatitis have enhanced amounts of antibodies against lipid peroxidation 
products and there is a high amount of T cells in the liver, suggesting that of 
adaptive immunity plays a role in alcoholic liver disease, including 
alcoholic hepatitis. Chronic ethanol intake increases free radical stress, 
which generates lipid peroxidation products such as malondialdehyde and 4-
hydroxynonenal; which can modify many biomolecules, inducing the 
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formation of protein products which can behave like epitopes to activate the 
corresponding adaptive response. However, the exact ways by which 
adaptive immune responses produce liver cell toxicity and organ 
dysfunction in subjects with alcoholic hepatitis are under study. 
Blockade of regenerative response : The liver is a resilient organ 
capable of great recovery; regeneration of liver cells  occurs principally by 
reproduction by remaining unaffected liver cells, cholangioepitheliocytes, 
and vessels wall structures. In conditions where these cells are prevented 
from reproducing, native liver progenitor cells, ductular hepatocytes, 
increase in number and transform into liver cells or epithelial cells of the 
biliary tract. There has been a study which showed reduced liver cell 
division post hepatectomy in chronic ethanol intake but the direct morbidity 
ethanol causes on liver cell reproduction and proliferation is yet to be 
understood. It is not farfetched to now imagine that chronic ethanol intake 
not only causes liver cell apoptosis but significantly hinders liver cell 
regeneration, adding to another of the multivarious ways alcohol may 
induce hepatocytic damage in alcoholic liver disease 
Collagenic regeneration of liver: Liver fibrosis is a regenerative 
response to practically all forms of chronic liver injury; it is typified by 
predominant deposition of extracellular matrix proteins especially collagen. 
The major source of this collagen and other extracellular matrix proteins is 
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by haematopoetic stem cells. Other cells involved in this are portal 
fibroblasts and myofibroblasts derived from the haematopoetic marrow. The 
haematopoetic stem cells are derived from autocoids, angiogenic factors, 
cytokines, chemokines, chemicals of innate immunity, and other molecules 
which are secreted due to liver cell injury. Fibrogenic response, being a 
typical terminal common pathway for prolonged and persistent significant 
liver cell injury, is similar in alcohol related injury as is with other causes of 
liver injury, although some aspects of the fibrogenic response cascade may 
be unique to alcohol.  
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FIGURE  - 4 
 
LPS activates TLR4: Most patients with alcoholic liver disease have 
increased levels of Lipopolysaccharide. LPS can directly or indirectly 
stimulate the haematopoetic stem cells. First, it can directly activate them 
via Toll like Receptor-4. And secondly, it can activate free radical stress in 
the Kupffer cells and a cytokine increase which in turn activate the stem 
cells. Angiogenesis, which can also result in fibrogenesis, is activated by 
TLR-4 mediated stimulation of sinusoidal endothelial cells. Thus one can 
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safely say that TLR-4 signaling plays a major role in the fibrotic process. 
There was a recent report using chimeric mice in which wild-type mice 
underwent transplant with bone marrow cells from TLR4 knockout mice 
and vice versa, which showed inhibition or slow down of the fibrotic 
process when TLR-4 mediated mechanisms were shut down in the host. 
 Activation of HSCs by acetaldehyde: Acetaldehyde is generated 
mainly by liver cells and acts on HSCs in a paracrine fashion; it linearly 
increases synthesis of collagen I in HSCs via amplification of various 
signaling cascades and regulatory factors. Acetaldehyde also combines 
swiftly with cellular components, producing dangerous adducts such as 
malondialdehyde, 4-hydroxynonenal, and malondialdehyde-acetaldehyde, 
which result in a sustained HSC activation. 
 Alcohol inhibiting antifibrotic mechanisms:  A major anti fibrotic 
mechanism in cells is in the form of activated natural killer cells which 
destroy haematopoeticstem cells or by producing interferon-γ,which induces 
cell cycle checks in the stem cells. Long term alcohol consumption results in 
weakening and stunting of this response. This could potentially explain 
fibrosis in alcohol intake as well as enhanced premature fibrosis in patients 
with viral hepatitis who also consume alcohol. 
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FIGURE  - 5 
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TREATMENT 
 People who are suffering from this terrible disease must be subjected 
to treatments to kick the habit, i.e. deterrents. It is an established fact that 
continued alcohol intake is the single most important risk factor for further 
disease progression. One must be able to recognize and accept the problem 
first. 
CAGE Questionnaire and AUDIT questionairre: 
 
FIGURE  - 6 
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Another factor significant in this scenario is that of transplantation 
and the fact that patients who continually expose themselves to the toxic 
effects of alcohol, preclude themselves from eligibility for transplantation. 
Patients need to be taken care of under special rehabilitation programs. 
There are many possible options for pharmacological treatment for alcohol 
dependence. The irreversible inhibitor of alcohol dehydrogenase, 
Disulfiram, is often used, but its use must be weighed against the risk of 
serious hepatotoxicity in patients who already have compromised liver 
function and reserve. Another drug, Acamprosate is also similar in side 
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effect profile. The GABA-B agonist, Baclofen is also useful and may, in 
fact, be the safest of the three fr aiding abstinence. The opioid antagonist 
naltrexone has been found to decrease relapse, although its efficacy is 
limited. 
Currently there are no approved antifibrotic drugs to prevent disease 
progression in patients with alcoholic liver disease. There do exist only 
ways to assess the extent of fibrosis using imagine or biopsy studies. There 
are many confounding factors that need to be taken in during trials like the 
positive outcome that may arise due the fact that patients alter drinking 
patterns once they are fully enrolled in trials. 
When it comes to full blown cirrhosis, patients who have a reduced 
drinking pattern have a much slower progression of cirrhosis subsequently, 
than patients who do not. Apropos, patients who drink on top of existing 
cirrhosis predispose themselves to subsequent steatohepatitis of the existing 
parenchyma and decompensation. The only established facts about 
treatment of alcoholic cirrhosis remain that firstly, the regimens are the 
same as that for cirrhosis for other causes, and secondly, the only addition 
therapeutic intervention currently of established value, is alcohol abstinence. 
Alcoholic hepatitis, represents a potentially serious aspect of 
alcoholic liver disease; its treatment has been described by the following: 
21 
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TREATMENT OF AH 
SUPPORTIVE TREATMENT :  
 Patients with alcoholic hepatitis may be sick enough to require critical 
care. Depending on the degree of encephalopathy, airway protection may be 
necessary. During procedures, usage of CNS suppressants like 
benzodiazepines should not be used. Given that most of these patients may 
be intoxicated at the time of presentation or may have a severely depleted 
thiamine store, restoration of thiamine levels will also have to be taken care 
of, lest Wernicke’s encephalopathy is precipitated. Owing to the severe 
susceptibility to infections these people may be prone for, or the fact that 
very often it is an infection that precipitates these episodes, antibiotics 
should be administered either therapeutically or empirically. 
CORTICOSTEROIDS:  
 The addition of steroids to alcoholic hepatitis treatment repertoire was 
by Maddrey et al in 1978 when a randomized double blinded control trial 
which studied the use of corticosteroids in the test arm in 55 patients with 
alcoholic hepatitis. But since then there have been several meta-analyses 
that have refuted claims of utility of steroids. Also, multiple meta-analyses 
alleged that steroids enhanced duration of survival amongst subjects , but 
one in particular alleged bias in some trials, therefore not advocating its use. 
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These conflicting opinions notwithstanding, the American Association for 
the Study of Liver Diseases recommends the prescription of corticosteroids 
in the setting of a severe alcoholic hepatitis, where a Maddrey’s  
discriminant factor is greater than 32, and/ or the patient develops profound 
hepatic encephalopathy. Consequently, these steroids also worsen risk of 
infection and any patient with a significant evidence of infection when 
under steroid therapy must be monitored. Another index exists which 
suggests the benefit of the use of steroids in such patients at the end of one 
week of steroid therapy- called the Lille score, a score of >0.45 indicating 
poor benefit from steroids and a six month survival rate of less than one-
fourth of patients. Some laboratory studies have shown that in clinical cases 
where alcoholic hepatitis is severe, the usual accompanying steroid 
refractoriness is reduced by Theophylline, a fact that still needs to be 
established in-vivo. Thus there may be a bigger role for steroids after all. 
PENTOXIFYLLINE:   
 Another agent of particular interest is this phosphodiesterase 
inhibitor. Its main action seems to be to suppress circulating IFN-alpha 
levels by reducing its transcription. Historically it has been used to treat 
those patients who simply cannot be given steroids. The reduced mortality 
hitherto suggested at for pentoxifylline may be due to its protective effect 
over hepatorenal syndrome. Recent studies, though, have shown that the 
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effects of this drug must be viewed with some amount of caution as it may 
not be beneficial at all. The efficacy of this drug may be very much reduced 
compared to steroids as those who were treated with this drug as a rescue 
therapy for steroid refractoriness have not improved.  
Anti-TNF-α agents :  
 As TNF- α has been strongly implicated in the pathogenesis in animal 
models, trials have been conducted where inhibitors of this cytokine have 
been used. Although there may have been a benefit in terms of improvement 
of the hepatitis, they greatly increase mortality and morbidity due to the 
increased risk of infections. Thus currently the use of these agents is not 
advised. 
NUTRITION THERAPY:  
 Directly due to behaviour and due to malabsorption, lots of these 
patients experience malnourishment which needs to be addressed. Apart 
from the overall patient benefit that comes with better nourishment, patients 
also experience an improvement in survival in terms of better liver function 
as witnessed by more rapid recovery of liver function tests in the short term 
and an improved histology profile in those whose nutritional status has been 
improved. 
 
25 
 
SAMe:  
 This is a methyl donor which has been found in many studies to have 
a good impact on the patient profile, by inhibiting tnf- α, by improving 
mitochondrial function, and good antioxidant action thereby protecting 
against free radical stress. Its minimal adverse effect profile aside, it also 
aided in a noticeable improvement in outcome of patients and a reduced 
need for hepatic replacement therapy.  But one Cochrane review ascertained 
that there was no benefit in using this drug in alcoholic hepatitis. Further 
studies may be needed before the verdict can be decided either way. 
LIVER TRANSPLANTATION:   
 Finally, liver transplantation can be used as a last resort in those with 
severe decompensation. The outcomes for transplantation in the setting of 
alcoholic liver disease are the same if not better than when done for other 
indications. Thus, although a preliminary half year abstinence is required for 
any patient to undergo a liver transplant, arguments have been made for 
transplantation to be a salvage therapy for those, who, otherwise fulfill 
criteria for transplantation as well as a thorough psychiatric exam.  
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OTHER THERAPIES:  
 Attempts have been made to use anabolic androgenic steroids to 
increase muscle bulk and improve nutritional status. Meta analysis of these 
trials showed no improved benefit and are thus not recommended. The 
antithyroid medication Propylthiouracil has been suggested and tried out in 
patients with alcoholic hepatitis. But no benefit was found. The use of 
antioxidants, counter intuitively, has not shown any significant benefit. The 
drugs included in the trial were Vitamin E and Silymarin. But there is hope 
in the horizon as N-acetylcysteine may be of some benefit in conjunction 
with corticosteroids. Further studies are needed to establish this idea. 
NEWER POTENTIAL TARGETS: 
 Considering the fact the animals seem to be far more resilient to the 
development of alcoholic cellular injury and portal hypertension, it has been 
difficult transposing findings in animal models to clinical practice. Those 
animal models that have significantly similar injury patterns to live patients 
with alcoholic liver injury need to be studied deeply. Another factor that 
needs to be taken into account is the fact that some molecules and cytokines 
may simply be elevated due to concomitant infection which almost always 
accompanies alcoholic liver disease and its decompensations. Thus a 
retrospective approach of finding molecules that are significantly in clinical 
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patients and then using that knowledge to test out the validity of the 
molecule in a laboratory setting would be prudent. Some stand out instances 
of such approaches under trial would be: 
CXC CHEMOKINES:  
 Neutrophilic attack is one of the cardinal features of alcoholic liver 
disease and alcoholic hepatitis. This family of cytokines especially IL-8 and 
gro- α . Some studies have shown that, not only are these increased in 
patients with alcoholic hepatitis, but their levels also correlate well with 
disease activity time and are inversely proportional to survival duration. 
This is a potential target that must be looked into. 
INTERLEUKIN-22:  
 It belongs to the IL-10 family of cytokines. It is primarily involved 
with microbe related immunity, a steady state functioning and regeneration. 
It protects cells from inflammation, oxidative cell stress, and prevents 
indirect alcohol medicated apoptosis. Considering the target receptors for 
this molecule are only present on certain cells, its use might be pretty safe. It 
could also work synergistically with steroids as the increased risk of 
infection could be counterbalanced by the antimicrobial activity of IL-22. 
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COMPLEMENT CASCADE INHIBITION:   
 The activation of complement and complement mediated cell lysis is 
an important facet of alcohol mediated liver injury. Developing therapies to 
inhibit the complement cascade may be of help. 
MICROFLORA OF THE ALIMENTARY TRACT:  
 The role of rifaximin in liver disease is now well established. Patients 
who have a microbial overgrowth consistently have a worse outcome. 
Similarly the role of LPS in the pathogenesis of alcoholic liver disease is 
highly suggestive. Thus agents that can antagonize its action at a pre-
receptor or a receptor level may well be of benefit. 
INHIBITION OF APOPTOSIS:  
 Multiple trials have suggested the use of caspase inhibitors as a future 
therapeutic tool in liver diseases where apoptosis of hepatocytes is present 
extensively, like hepatitis C and steatohepatitis. Similarly it can also be tried 
in alcoholic liver disease along with IL-22. 
BONE MATRIX PROTEINS:  
 Peculiarly, osteopontin has been found to be expressed in 
significantly elevated amounts in patients with alcoholic liver disease. Once 
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it can be established that it is a molecule involved in the pathogenesis, it can 
be a potential target. 
ENDOGENOUSLY SYNTHESIZED CANNABINOIDS:   
 There have been instances where endocannabinoids and their 
receptors have been upregulated in the setting of Alcoholic liver disease. 
NOSTRIN:  
 Increased nostrin expression may lead to decreased levels of eNOS 
which leads to the decreased nitric oxide found in alcoholic liver disease 
patients. 
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BETAINE 
Betaine or trimethyglycine is a substance found in a variety of plant 
products in nature, originally first isolated from the juice extracted from 
sugar beet. It may be produced as an intermediary metabolite in the body as 
well, by the oxidation of choline. It possesses several properties that have 
made it useful in the treatment of non alcoholicsteatohepatitis across the 
years, in the form of betaine hydrochloride, which being a substance found 
across different natural food products, its side effect profile is expected to be 
extremely favourable. For those reasons, it would appear to be an interesting 
candidate to be tried for steatosis and liver dysfunction due to other causes 
as well. 
 
FIGURE  - 7 
 
 Chemical properties of the drug: Trimeth
of  an N-trimethylated amino acid which makes it a 
compound. It forms a 
mineral acids, it is converted to TMG of various salts, for example yielding 
betaine hydrochloride:
(CH3)3N+CH2CO2
Chemical formula
Molar mass
Appearance
Melting point
Solubility in water
Solubility 
Acidity (pKa)
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FIGURE  - 8 
ylglycine exists in the form 
quaternary ammonium
zwitterion at pH 7 - the neutral pH. On reaction with 
 
− + HCl → [(CH3)3N+CH2CO2H]Cl
Properties 
 C5H11NO2 
 117.146 
 White solid 
 180 °C (356 °F; 453 K) (decomposes)
 Soluble 
Methanol 
 1.84 
 
 
 
− 
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 Pharmacological actions of betaine in lower organisms: TMG is an 
amino acid derived osmolyte that is present in high concentrations 
(centiosmolars) in many oceanic invertebrates, like crustaceans and 
molluscs. It serves as a crucial appetitive attractant to generalist non-
herbivores such as the carnivorous sea-slug Pleurobranchaea californica. 
TMG is a critical cofactor in methylation, the biochemical reaction that 
happens in each cell of mammals to create and share methyl groups (CH3) 
for similar reactions in the cell. These reactions include the production of 
versatile hormones and autocoids such as dopamine and 5-
hydroxytryptamine. Methylation reaction is also used for the synthesis of 
melatonin and the mitochondrial electron transport chain intermediate 
coenzyme Q10.The crucial step in the methylation cycle is the 
remethylation of homocysteine, which will occur through either of two 
processes. The major cascade is through the enzyme methionine synthase, 
which requires Cobalamin as a cofactor, and thus also depends indirectly on 
folic acid and a multitude of other B vitamins. The minor process involves 
betaine-homocysteinemethyltransferase and uses TMG as a cofactor. 
Betaine is thus involved in the production of many biologically essential 
moieties, and may be even more critical in conditions where the major 
process for the repleting of methionine from homocysteine has been 
obstructed. Salmon farms use betaine to reduce the osmotic pressure on the 
fish’s cells when they are transferred from freshwater to saltwater. 
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TMG administration reduces the amount of adipose tissue in pigs 
DIETARY SOURCES OF BETAINE:  
 Betaine is found in a wide variety of naturally occurring foodstuffs 
like vegetables- beetroot,  spinaches and also in various cereals like quinoa 
and wheat bran. 
 
 
FIGURE  - 9 
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CHEMICAL PRODUCTION OF BETAINE:  
 Producing table sugar from sugar beets offers betaine as byproduct. 
The amount of betaine contained in sugar beets rivals its sugar content.  
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Betaine production requires, also, separation by chromatography. 
 
FIGURE  - 10 
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Biosynthesis of betaine in lower organisms: In many organisms, 
betaine is biosynthesized by oxidation of choline as a two step process. The 
intermediate, betaine aldehyde, is synthesised by the activity of the 
mitochondrial enzyme choline oxidase (A.K.A.choline dehydrogenase, EC 
1.1.99.1). Betaine aldehyde is subsequently oxidised in the mitochondria of 
mice to betaine by the enzyme betaine aldehyde dehydrogenase (EC 
1.2.1.8). In humans, though, betaine aldehyde activity is undertaken by a 
nonspecific cytoplasmic aldehyde dehydrogenase (EC 1.2.1.3) 
Synthesis of betaine in plants 
 
FIGURE  - 11 
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Reactions of betaine in Bacillus subtilis 
 
FIGURE  - 12 
BIOCHEMICAL REACTIONS OF BETAINE: 
 The reactions driven by betaine leading to its use are: (1) Its ability to 
act as a methyl group donor  in the biochemical reaction for the conversion 
of to methionine of homocysteine by a methyl transferase; (2) ability to act 
as a proxy for the ubiquitous methyl group donor for S-adenosylmethionine 
(SAM) in a reaction where phosphatidylethanolamine in directly methylated 
to phosphatidyl choline; (3) its protective actions against free radical stress; 
38 
 
(4) it’s vital facilitatory role in transsulfuration reactions; (5) metabolic 
stimulatory effect of adenosine monophosphate -activated protein kinase; 
and (6) its strong lipotropic property; (7) its ability to be osmotically active. 
METHYLATION REACTION AND BETAINE: 
 
FIGURE  - 13 
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FIGURE  - 14 
Betaine and its interactions with SAM 
Degradation of betaine: TMG upon demethylation reaction would 
yield dimethylglycine. Complete chemical lysis of TMG yields 
trimethylamine, the compound giving off the odour of rotten fish. 
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FIGURE  - 15 
SIDE EFFECT PROFILE:  
 Patients in previous studies had complained of nausea, bloating, 
heartburn, constipation, diarrhoea, body odour and itching. Rarely patients 
also complained of worsening of their peptic ulcer pain. The exact 
incidences or each adverse reaction was not quantified. No trial reported any 
serious or fatal adverse reaction to the drug. The drug is currently pregnancy 
category C and it is not yet known whether the drug is excreted in breast 
milk. So currently it is not recommended in pregnancy and lactation. 
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DOSING :  
 A wide range of doses have been given in previously published 
studies. The overall dosing range is 6-20g/day in two divided doses. The 
drug is usually given as a suspension in a solution or water, or as capsules.  
Utility in NAFLD:  
 Betaine, has yet to be tried in the setting of alcoholic liver disease. 
Upto 2011, four studies of betaine for the treatment of Non alcoholic fatty 
liver disease had been reported. The first one, a study by Miglio et al could 
not be considered too seriously as liver biopsy and microscopy was not used 
to qualify the patients as having non alcoholic fatty liver disease or not, 
which would put the patient sample set and overall statistical relevance into 
serious question. The study was published in 2000, being a randomised 
control trial with double blinding where the patients were given twice a day 
for eight weeks, oral betaine glucuronate along with diethanolamine 
glucuronate and nicotinamide ascorbate or placebo. The next trial was by 
Abdelmalek et al who, in 2001, attempted to use anhydrous betaine on ten 
patients. The study design was a prospective trial but without a control arm, 
and so, no blinding the duration of study was for one year out of which three 
patients did not even finish the trial, although they did experience an 
improvement of their liver transaminases in their truncated stay in the trial. 
Three patients would go on to enjoy complete normalization of their 
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transaminases. Three other patients would go on to have improvements 
while one patient did not respond. Along with the biochemical parameters 
mentioned above, patients were also subjected to liver biopsies for the 
purpose of diagnosis and for the purpose of follow up and up- and down-
staging of the illness which included degree of steatosis, necroinflammatory 
grade, and stage of fibrosis after completion of one year of betaine therapy. 
The size and the lack of placebo, randomization or blinding castes serious 
aspersions about the validity of the study. Credit, though, still does need to 
be given as it was a pilot study that paved the way for the rest of us to probe 
further into this drug. Mukherjee et al between 2003 and 2006 performed a 
study on thirty five NASH patients who were chosen based on elevated 
transaminases and liver biopsies being performed within one year of entry 
into the study and having satisfied the brunt criteria for non alcoholic fatty 
liver disease, who were then treated with anhydrous betaine ten grams twice 
a day, for one year. They reported an improvement in transaminases and 
stage of illness, and a overall better outcome with respect to hepatic fibrosis. 
Although the study appeared promising, it was a cohort study and there was 
no control arm or blinding. Abdelmalek et al subsequently reported the 
results of their second study in may 2010 . The primary aim of this study 
was to administer ten grams of betaine twice a day and to assess 
transaminase response. The secondary aim would go on to be determined by 
histopathology. The total size of this study would include thirty five patients 
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who would complete the trial (seventeen betaine vs eighteen placebo), 
which apart from liver function tests and liver biopsies, also included 
adipokines levels, basic cytokines, serum homocysteine levels, S-
adenosylhomocysteine (SAH), and the  liver biopsies were scored according 
to the Brunt criteria. The study went on to declare that they found no 
statistically significant improvement in betaine group with respect to the 
transaminases or the liver biopsies and the improvements seen in either arms 
of the study were spontaneous and similar. Betaine had shown no 
appreciable impact on adiponectin, cytokine, and SAH levels. The effect of 
betaine on the biopsies and histopathology were also placid, with no impact 
on fibrosis during the study as was claimed by earlier studies. Of even more 
significance, more patients in the placebo arm had a significant 
improvement in the steatosis grade (twenty nine percent vs sixty one 
percent, with a ‘p’ value less than 0.01) by more than one point, than the test 
arm. Slightly confounding though, was the fact that more test patients 
compared to placebo (seventy one percent vs twenty two percent, with a ‘p’ 
value of less than 0.005) had a stabilized steatosis grade during the study. 
The above trial would have categorically meant that betaine should 
have fallen completely out of favour with researchers in the field of non 
alcoholic liver disease. But the above studies quoted, with the last one 
included, do have some expressedly bewildering and sometimes, basic 
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limitations which will, even on retrospect, always lead us to question the 
underlying validity of each study and its respective outcomes and 
inferences. It is deeply distressing and confounding to find studies where 
there is a massive attrition load, especially of more than ten percent. How it 
would be possible to fill such huge gaps or extrapolate observational results 
in the setting of such large patient losses was an important question to come 
up with answers for and rectify. Some observers had commented that since 
the nature of non alcoholic fatty liver disease was so chronic that perhaps, 
even improvements would take that long. To add to worries, there exists no 
clear dosing regimen or efficacy study to ascertain what could be the 
possible dose required to even attempt using betaine in this setting. The 
dosages administered in the above trials were simply modified and shoe-
horned versions of what the dosing is for homocystinuria for which 
anhydrous betaine in approved. Inadequacy in knowledge of the drug dosing 
can mean the drug could’ve been just right, too little or even too much. For 
example, study patients in the last mentioned trial had a significantly higher 
incidence of abdominal related adverse drug reaction (thirty three percent vs 
nine percent, ‘p’ value less than 0.05), and this only adds to our attrition 
headache. Perhaps administering protected forms of the drug in the form of 
capsules or coated preparations, or alternate suspensions of the drug or even 
development of a newer salt of the same parent drug may be of help. Even 
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more fundamental questions need to be asked about the lack of objective 
proof of adequate patient compliance during the study.  
But for every study that throws up problems and loopholes, there 
have always been ones where one’s curiosity has been kindled. A study on 
mice by Kathirvel et al showed that betaine reduced fatty change and also 
helped improve insulin resistance and overall showing some sort of 
protective benefit in animal models shows why persisting with betaine still 
makes ample sense. It is obvious that subsequent studies will have to have 
tighter protocols and more care to prevent confounding factors from 
obscuring statistical data and assessment of outcomes. These mechanisms of 
alcoholic liver disease and non alcoholic liver disease do exhibit some 
common traits in terms of cellular pathogenesis. There has been no idea 
hitherto, to ascertain the benefits of this drug in the setting of alcohol related 
disease. Betaine, having demonstrated such a wide variety of biochemical 
actions in the liver cell, must be experimented with due to its considerably 
harmless side effect profile and its low cost. The fact that it does not seem to 
be a hit or miss drug or a drug with a lethal safety margin or any of that sort 
means that, at the very least, betaine in the future can be used as a great 
adjunct to a later discovery, if at all it does prove to be unsatisfactory as a 
mainstay. Other diseases where there has been use of betaine: 
Homocystinuria, Achlorhydria, Aminoaciduria, poliomyelitis. 
  
 
MATERIALS  
AND  
METHODS 
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MATERIALS AND METHODS 
Duration of the Study :  
 6 months 
Study Design:  
 Randomized Control Study with Single Blinding and Comparison 
with Placebo 
Sample Size:  
 40 patients 
Inclusion Criteria:  
1. Patients age >35 with  acute on chronic liver disease secondary to               
alcohol consumption as evidenced by at least one new onset 
appearance of :-   
a. jaundice, upper GI bleed, hepatic encephalopathy, 
coagulopathy, spontaneous bacterial peritonitis; in the presence 
of increased liver enzymes  
2. Maddrey score >3 
3. Past or present alcohol dependence or withdrawal; or consumption of 
alcohol > 10 drinks/ week for more than five years at any point in 
time; or patients with any one criteria positive in the CAGE 
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questionnaire at any point in time in the present or past. 
4. The acute decompensation may be of any cause. 
 
Exclusion Criteria:  
1. Age 35 or less 
2. Patients in whom the liver disease may be ascribed to any other cause 
eg. Viral hepatitis, intermediary metabolism defects 
3. Patients in whom the maddrey score is below 32 
4. Diabetic patients 
5. Patients with alcoholic hepatitis without evidence of underlying 
chronic liver disease 
 
Data Collection and Methods:  
 Patients selected for clinical study as per inclusion / exclusion criteria  
are subjected to routine blood investigations like complete hemogram, renal 
function tests, serum electrolytes, liver function tests, coagulogram, 
ultrasound of the abdomen, glycemic profile, screening for hepatitis viruses 
A to E. Detailed clinical examination will be done. Both groups of patients 
will be subjected to an upper GI endoscopy at the time of inclusion. The 
cause of that episode of decompensation shall be investigated and duly 
noted to better subcategorize the response patterns. Test Patients will be 
given oral therapy with betaine 3g b.d. for 3 months with other standard 
prescribed drugs while control patients will be given a placebo. Patients will 
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be followed up weekly during the study period where they will be subjected 
to a full physical exam and routine blood tests in the form of complete blood 
count, renal and liver function tests, and coagulogram. They will be 
subjected to a repeat upper GI endoscopy at the end of the study period. 
Product / Procedure / Investigation Details:  
1. Complete blood count 
2. Renal function test 
3. Liver function test 
4. Coagulogram 
5. Detection of markers for viral hepatitis 
6. Glycemic Profile 
7. Upper GI Endosopy 
8. Ultrasonogram of the abdomen 
 
Ethical Committee approval :  Obtained 
  
  
 
OBSERVATION  
AND  
RESULTS 
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OBSERVATION AND RESULTS 
This study was done to determine the effects on betaine therapy on 
acute on chronic alcoholic liver disease. 40 patients were chosen under the 
inclusion criteria and 20 of them were subjected to the drug while 20 were 
subjected to placebo therapy. The following data was obtained based on the 
data collected as part of the study: 
 
TABLE 1 : AGE OF SUBJECTS 
 
 
 
AGE 
Mean 
Media
n 
Minim
um 
Maxim
um 
Standard 
Deviation 
Standard 
Error of 
Mean 
group 
Experiment 54.45 56.00 41.00 63.00 7.06 1.58 
Control 54.30 54.00 39.00 68.00 7.55 1.69 
 
p>0.05, No difference between two groups among 2 groups 
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TOTAL BILIRUBIN: 
 
TABLE 2 : MEASURE: T_BILIRUBIN 
 
group WEEKS Mean Std. Error 
95% Confidence Interval 
Lower 
Bound Upper Bound 
Experiment 
1 13.51 .485 12.529 14.491 
2 12.46 .194 12.071 12.856 
3 12.55 .216 12.113 12.988 
4 12.59 .303 11.985 13.211 
5 12.25 .269 11.713 12.802 
6 9.11 .787 7.517 10.705 
7 7.39 .513 6.353 8.428 
8 6.92 .247 6.429 7.428 
9 6.60 .198 6.204 7.005 
10 3.15 .214 2.725 3.591 
11 3.08 .201 2.678 3.494 
12 3.42 .367 2.681 4.168 
13 3.39 .346 2.689 4.090 
Control 
1 12.38 .485 11.399 13.361 
2 12.46 .194 12.075 12.861 
3 13.05 .216 12.612 13.487 
4 13.11 .303 12.503 13.728 
5 13.18 .269 12.643 13.732 
6 11.28 .787 9.687 12.875 
7 7.43 .513 6.399 8.474 
8 6.87 .247 6.377 7.377 
9 6.66 .198 6.263 7.064 
10 3.78 .214 3.354 4.220 
11 3.13 .201 2.724 3.540 
12 3.52 .367 2.785 4.272 
13 3.52 .346 2.823 4.225 
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PAIRWISE COMPARISONS 
 
 
TABLE 3 : MEASURE: T_BILIRUBIN 
 
 
(I) group (J) group 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.
a
 
95% Confidence Interval 
for Differencea 
Lower 
Bound 
Upper 
Bound 
Experiment Control -.304 .175 .091 -.659 .051 
Control Experiment .304 .175 .091 -.051 .659 
 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent to 
no adjustments). 
 
THE ABOVE TABLES DEPICTS THERE IS SIGNIFICANCE 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN  EXPERIMENTAL 
AND CONTROL GROUP 
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TABLE 4 : DIRECT BILIRUBIN 
 
4. group * WEEKS 
Measure: d_billrubin 
group WEEKS Mean Std. Error 95% Confidence Interval 
Lower Bound Upper Bound 
Experiment 
1 13.51 .485 12.529 14.491 
2 12.46 .194 12.071 12.856 
3 12.55 .216 12.113 12.988 
4 12.59 .303 11.985 13.211 
5 12.25 .269 11.713 12.802 
6 9.11 .787 7.517 10.705 
7 7.39 .513 6.353 8.428 
8 6.92 .247 6.429 7.428 
9 6.60 .198 6.204 7.005 
10 3.15 .214 2.725 3.591 
11 3.08 .201 2.678 3.494 
12 3.42 .367 2.681 4.168 
13 3.39 .346 2.689 4.090 
Control 
1 12.38 .485 11.399 13.361 
2 12.46 .194 12.075 12.861 
3 13.05 .216 12.612 13.487 
4 13.11 .303 12.503 13.728 
5 13.18 .269 12.643 13.732 
6 11.28 .787 9.687 12.875 
7 7.43 .513 6.399 8.474 
8 6.87 .247 6.377 7.377 
9 6.66 .198 6.263 7.064 
10 3.78 .214 3.354 4.220 
11 3.13 .201 2.724 3.540 
12 3.52 .367 2.785 4.272 
13 3.52 .346 2.823 4.225 
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PAIRWISE COMPARISONS 
TABLE 5 : MEASURE: D_BILIRUBIN 
(I) group (J) group 
Mean 
Difference 
(I-J) 
Std. 
Error Sig.
a
 
95% Confidence 
Interval for Difference 
Lower 
Bound 
Upper 
Bound 
Experiment Control -.304 .175 .091 -.659 .051 
Control Experime
nt .304 .175 .091 -.051 .659 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent 
to no adjustments). 
 
 
 THE ABOVE TABLES DEPICTS THERE IS SIGNIFICANCE 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN EXPERIMENTAL 
AND CONTROL GROUP 
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LIVER ENZYME- SGPT 
TABLE 6 : SGPT  
Measure: pt_ 
group WEEKS Mean Std. Error 95% Confidence Interval 
Lower Bound Upper Bound 
Experiment 
1 170.850 9.143 152.340 189.360 
2 176.600 3.165 170.192 183.008 
3 172.300 3.404 165.409 179.191 
4 170.650 3.292 163.986 177.314 
5 175.900 4.367 167.059 184.741 
6 131.100 5.632 119.698 142.502 
7 126.700 3.349 119.920 133.480 
8 120.350 3.302 113.665 127.035 
9 124.500 3.357 117.704 131.296 
10 70.400 3.286 63.748 77.052 
11 83.100 6.289 70.369 95.831 
12 78.700 4.812 68.959 88.441 
13 74.050 3.594 66.774 81.326 
Control 
1 156.950 9.143 138.440 175.460 
2 174.850 3.165 168.442 181.258 
3 176.450 3.404 169.559 183.341 
4 177.600 3.292 170.936 184.264 
5 177.500 4.367 168.659 186.341 
6 123.250 5.632 111.848 134.652 
7 122.500 3.349 115.720 129.280 
8 124.300 3.302 117.615 130.985 
9 130.500 3.357 123.704 137.296 
10 70.100 3.286 63.448 76.752 
11 66.250 6.289 53.519 78.981 
12 67.600 4.812 57.859 77.341 
13 67.250 3.594 59.974 74.526 
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PAIRWISE COMPARISONS 
TABLE 7 : PAIRWISE COMPARISONS  
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.a 95% Confidence Interval 
for Differencea 
Lower 
Bound 
Upper 
Bound 
Experiment Control 3.085 2.143 .158 -1.254 7.423 
Control Experime
nt -3.085 2.143 .158 -7.423 1.254 
 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent 
to no adjustments). 
 
THE ABOVE TABLES DEPICTS THERE IS SIGNIFICANCE 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN  EXPERIMENTAL 
AND CONTROL GROUP 
 
TABLE 8 Liver Enzyme- SGOT 
 
4. group * WEEKS 
Measure: ot_ 
group WEEK
S 
Mean Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Experime
nt 
1 394.500 12.410 369.377 419.623 
2 333.650 20.168 292.822 374.478 
3 318.600 17.889 282.385 354.815 
4 376.500 18.115 339.829 413.171 
5 325.500 19.006 287.024 363.976 
6 199.550 9.838 179.633 219.467 
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7 187.150 1.767 183.573 190.727 
8 187.650 1.770 184.066 191.234 
9 187.950 1.639 184.633 191.267 
10 63.350 3.704 55.852 70.848 
11 77.250 12.814 51.309 103.191 
12 71.900 10.878 49.879 93.921 
13 72.200 6.645 58.748 85.652 
Control 
1 386.350 12.410 361.227 411.473 
2 347.700 20.168 306.872 388.528 
3 322.950 17.889 286.735 359.165 
4 348.150 18.115 311.479 384.821 
5 353.700 19.006 315.224 392.176 
6 195.450 9.838 175.533 215.367 
7 186.700 1.767 183.123 190.277 
8 187.250 1.770 183.666 190.834 
9 189.000 1.639 185.683 192.317 
10 69.850 3.704 62.352 77.348 
11 77.750 12.814 51.809 103.691 
12 87.400 10.878 65.379 109.421 
13 72.300 6.645 58.848 85.752 
 
 
Pairwise Comparisons 
TABLE NO . 9 Measure: ot_ 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.a 95% Confidence Interval 
for Differencea 
Lower 
Bound 
Upper 
Bound 
Experime
nt Control -2.215 4.993 .660 -12.323 7.892 
Control Experime
nt 2.215 4.993 .660 -7.892 12.323 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference 
(equivalent to no adjustments). 
THE ABOVE TABLES DEPICTS THERE IS SIGNIFICANCE 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN  EXPERIMENTAL 
AND CONTROL GROUP 
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TABLE NO. 10 Liver Enzyme Alkaline Phosphatase 
 
4. group * WEEKS 
Measure: alp_ 
group WEEK
S 
Mean Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Experime
nt 
1 62.700 2.553 57.531 67.869 
2 59.500 1.585 56.291 62.709 
3 61.500 1.433 58.598 64.402 
4 59.350 1.354 56.610 62.090 
5 60.500 1.379 57.707 63.293 
6 60.650 1.132 58.359 62.941 
7 60.850 1.241 58.337 63.363 
8 60.850 1.354 58.109 63.591 
9 59.850 1.602 56.608 63.092 
10 60.350 1.371 57.574 63.126 
11 62.050 1.321 59.377 64.723 
12 57.950 1.601 54.708 61.192 
13 59.600 1.325 56.918 62.282 
Control 
1 61.400 2.553 56.231 66.569 
2 61.400 1.585 58.191 64.609 
3 58.350 1.433 55.448 61.252 
4 62.000 1.354 59.260 64.740 
5 60.800 1.379 58.007 63.593 
6 59.150 1.132 56.859 61.441 
7 59.700 1.241 57.187 62.213 
8 60.550 1.354 57.809 63.291 
9 56.450 1.602 53.208 59.692 
10 62.400 1.371 59.624 65.176 
11 59.650 1.321 56.977 62.323 
12 61.300 1.601 58.058 64.542 
13 59.500 1.325 56.818 62.182 
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Pairwise Comparisons 
TABLE NO.11 Measure: alp_ 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.a 95% Confidence Interval 
for Differencea 
Lower 
Bound 
Upper 
Bound 
Experime
nt Control .235 .728 .749 -1.240 1.709 
Control Experime
nt -.235 .728 .749 -1.709 1.240 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference 
(equivalent to no adjustments). 
 
THE ABOVE TABLES DEPICTS THERE IS SIGNIFICANCE 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN  EXPERIMENTAL 
AND CONTROL GROUP 
 
TABLE NO.12 Total Protein: 
 
4. group * WEEKS 
Measure: t_protein 
group WEEK
S 
Mean Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Experime
nt 
1 5.51 .052 5.405 5.615 
2 5.21 .051 5.112 5.319 
3 5.18 .045 5.090 5.271 
4 5.26 .048 5.165 5.358 
5 5.27 .058 5.159 5.395 
6 5.23 .049 5.136 5.336 
7 5.20 .054 5.099 5.316 
8 5.25 .050 5.149 5.353 
9 5.16 .055 5.050 5.272 
10 5.20 .044 5.117 5.294 
11 5.20 .054 5.097 5.315 
12 5.20 .043 5.115 5.290 
13 5.26 .046 5.171 5.359 
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Control 
1 5.52 .052 5.415 5.625 
2 5.13 .051 5.033 5.240 
3 5.09 .045 5.006 5.187 
4 5.20 .048 5.107 5.300 
5 5.17 .058 5.059 5.296 
6 5.19 .049 5.090 5.290 
7 5.13 .054 5.025 5.242 
8 5.25 .050 5.157 5.361 
9 5.19 .055 5.086 5.309 
10 5.25 .044 5.167 5.344 
11 5.06 .054 4.953 5.171 
12 5.17 .043 5.085 5.260 
13 5.11 .046 5.017 5.205 
 
Pairwise Comparisons 
TABLE NO.13 Measure: t_protein 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.b 95% Confidence Interval 
for Differenceb 
Lower 
Bound 
Upper 
Bound 
Experime
nt Control .051
*
 .023 .032 .005 .098 
Control Experime
nt -.051
*
 .023 .032 -.098 -.005 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Least Significant Difference 
(equivalent to no adjustments). 
 
THE ABOVE TABLES DEPICTS THERE IS SIGNIFICANCE 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN  EXPERIMENTAL 
AND CONTROL GROUP 
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TABLE NO.14 Serum Albumin: 
 
4. group * WEEKS 
Measure: s_albumin 
group WEEK
S 
Mean Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Experime
nt 
1 2.61 .034 2.547 2.685 
2 2.58 .026 2.534 2.640 
3 2.58 .025 2.533 2.636 
4 2.57 .027 2.519 2.629 
5 2.60 .029 2.545 2.663 
6 2.60 .027 2.550 2.658 
7 2.60 .023 2.561 2.654 
8 2.62 .026 2.571 2.675 
9 2.55 .027 2.501 2.611 
10 2.60 .030 2.546 2.667 
11 2.54 .024 2.499 2.596 
12 2.60 .022 2.563 2.653 
13 2.58 .028 2.529 2.644 
Control 
1 2.58 .033 2.518 2.652 
2 2.54 .026 2.497 2.600 
3 2.55 .025 2.503 2.603 
4 2.60 .026 2.553 2.660 
5 2.59 .028 2.536 2.652 
6 2.57 .026 2.525 2.630 
7 2.63 .022 2.592 2.683 
8 2.60 .025 2.550 2.651 
9 2.62 .027 2.569 2.677 
10 2.59 .029 2.538 2.656 
11 2.53 .023 2.487 2.582 
12 2.54 .022 2.500 2.588 
13 2.61 .028 2.557 2.669 
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TABLE NO.15 Measure: s_albumin 
Pairwise Comparisons 
 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.a 95% Confidence Interval 
for Differencea 
Lower 
Bound 
Upper 
Bound 
Experime
nt Control .007 .012 .551 -.017 .031 
Control Experime
nt -.007 .012 .551 -.031 .017 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference 
(equivalent to no adjustments). 
 
p>0.05 no difference between group and weeks 
 
INR: 
 
TABLE NO.16 INR 
4. group * WEEKS 
Measure: inr_ 
group WEEK
S 
Mean Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Experime
nt 
1 4.35 .102 4.143 4.557 
2 3.48 .097 3.288 3.681 
3 3.55 .073 3.403 3.698 
4 1.99 .123 1.747 2.244 
5 2.31 .174 1.966 2.670 
6 2.02 .100 1.821 2.225 
7 1.89 .064 1.769 2.027 
8 2.01 .068 1.874 2.151 
9 2.06 .060 1.939 2.182 
10 1.87 .071 1.729 2.017 
11 2.00 .083 1.836 2.174 
12 1.98 .075 1.831 2.136 
13 2.02 .087 1.844 2.197 
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Control 
1 3.96 .102 3.753 4.167 
2 3.63 .097 3.436 3.830 
3 3.60 .073 3.453 3.748 
4 2.15 .123 1.903 2.400 
5 2.30 .174 1.956 2.660 
6 2.05 .100 1.850 2.253 
7 1.86 .064 1.739 1.997 
8 1.99 .068 1.858 2.135 
9 2.09 .060 1.973 2.216 
10 1.94 .071 1.797 2.085 
11 2.03 .083 1.867 2.205 
12 2.02 .075 1.876 2.182 
13 2.08 .087 1.904 2.257 
 
TABLE NO.17 PAIRWISE COMPARISONS 
 
Pairwise Comparisons 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.a 95% Confidence Interval 
for Differencea 
Lower 
Bound 
Upper 
Bound 
Experime
nt Control -.013 .036 .714 -.087 .060 
Control Experime
nt .013 .036 .714 -.060 .087 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference 
(equivalent to no adjustments). 
THE ABOVE TABLES DEPICTS THERE IS SIGNIFICANCE 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN  EXPERIMENTAL 
AND CONTROL GROUP 
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TABLE NO.18 HAEMOGLOBIN 
Haemoglobin: 
 
4. group * WEEKS 
Measure: HB_ 
group  WEEK
S 
Mean Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Experi
ment 
P<
0.0
5 
1 8.31 .306 7.691 8.929 
2 8.42 .327 7.763 9.087 
3 7.92 .322 7.273 8.577 
4 8.14 .320 7.492 8.788 
5 7.96 .319 7.314 8.606 
6 8.48 .322 7.834 9.136 
7 7.77 .319 7.125 8.415 
8 7.67 .319 7.030 8.320 
9 8.16 .320 7.512 8.808 
10 7.41 .320 6.766 8.064 
11 7.50 .320 6.858 8.152 
12 7.14 .325 6.483 7.797 
13 7.33 .323 6.676 7.984 
Contro
l 
P<
0.0
5 
1 7.96 .306 7.346 8.584 
2 7.85 .327 7.193 8.517 
3 7.38 .322 6.728 8.032 
4 7.66 .320 7.017 8.313 
5 7.47 .319 6.829 8.121 
6 7.95 .322 7.299 8.601 
7 7.28 .319 6.640 7.930 
8 7.19 .319 6.545 7.835 
9 7.66 .320 7.017 8.313 
10 6.90 .320 6.256 7.554 
11 7.00 .320 6.353 7.647 
12 6.62 .325 5.963 7.277 
13 6.81 .323 6.156 7.464 
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TABLE NO.19 HB 
 
Pairwise Comparisons 
Measure: HB_ 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
P 
VALUE 
95% Confidence Interval 
for Differencea 
Lower 
Bound 
Upper 
Bound 
Experime
nt Control .498 .449 .274 -.411 1.407 
Control Experime
nt -.498 .449 .274 -1.407 .411 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference 
(equivalent to no adjustments). 
THE ABOVE TABLES DEPICTS THERE IS SIGNIFICANCE 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN  EXPERIMENTAL 
AND CONTROL GROUP 
 
TABLE NO.20 PACKED CELL VOLUME 
Packed Cell Volume: 
 
4. group * WEEKS 
Measure: PCV_ 
group WEEK
S 
Mean Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Exper
iment 
P<0
.05 
1 26.30 .743 24.797 27.803 
2 24.20 .612 22.960 25.440 
3 23.35 .583 22.170 24.530 
4 23.45 .730 21.971 24.929 
5 21.70 .622 20.440 22.960 
6 23.80 .688 22.407 25.193 
7 22.70 .664 21.355 24.045 
8 23.15 .678 21.777 24.523 
9 23.55 .656 22.222 24.878 
10 22.35 .667 20.999 23.701 
11 21.40 .604 20.177 22.623 
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12 22.75 .668 21.398 24.102 
13 22.75 .708 21.317 24.183 
Contr
ol 
P<0
.05 
1 25.45 .743 23.947 26.953 
2 23.10 .612 21.860 24.340 
3 22.10 .583 20.920 23.280 
4 22.35 .730 20.871 23.829 
5 23.70 .622 22.440 24.960 
6 23.85 .688 22.457 25.243 
7 23.20 .664 21.855 24.545 
8 23.20 .678 21.827 24.573 
9 21.70 .656 20.372 23.028 
10 23.00 .667 21.649 24.351 
11 23.35 .604 22.127 24.573 
12 21.80 .668 20.448 23.152 
13 22.55 .708 21.117 23.983 
 
TABLE NO.21 PCV 
Pairwise Comparisons 
Measure: PCV_ 
 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.a 95% Confidence Interval 
for Differencea 
Lower 
Bound 
Upper 
Bound 
Experime
nt Control .162 .417 .700 -.682 1.005 
Control Experime
nt -.162 .417 .700 -1.005 .682 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference 
(equivalent to no adjustments). 
THE ABOVE TABLES DEPICTS THERE IS SIGNIFICANCE 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN  EXPERIMENTAL 
AND CONTROL GROUP 
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TABLE NO.22 WHITE CELL COUNT 
 
Total White Cell Count: 
 
4. group * week 
Measure: TC_ 
group  week Mean Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Exper
iment 
P<0.0
5 
1 10.510 .805 8.881 12.139 
2 7.352 .442 6.458 8.246 
3 7.545 .454 6.625 8.465 
4 7.394 .393 6.598 8.191 
5 8.393 .441 7.500 9.286 
6 7.713 .429 6.843 8.582 
7 7.499 .426 6.636 8.363 
8 7.258 .451 6.344 8.172 
9 7.750 .491 6.755 8.744 
10 6.827 .492 5.830 7.824 
11 7.816 .416 6.973 8.659 
12 7.915 .499 6.905 8.926 
13 7.892 .452 6.978 8.807 
Contr
ol 
P<0.0
5 
1 12.035 .805 10.406 13.664 
2 7.771 .442 6.878 8.665 
3 7.644 .454 6.724 8.564 
4 7.706 .393 6.910 8.503 
5 7.202 .441 6.310 8.095 
6 7.988 .429 7.118 8.857 
7 7.053 .426 6.190 7.916 
8 7.136 .451 6.222 8.049 
9 7.052 .491 6.058 8.047 
10 7.753 .492 6.756 8.750 
11 7.292 .416 6.450 8.135 
12 7.518 .499 6.508 8.529 
13 7.526 .452 6.611 8.440 
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TABLE NO.23 TC 
 
Pairwise Comparisons 
Measure: TC_ 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.a 95% Confidence Interval 
for Differencea 
Lower 
Bound 
Upper 
Bound 
Experiment Control .014 .215 .947 -.420 .449 
Control Experime
nt -.014 .215 .947 -.449 .420 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference (equivalent 
to no adjustments). 
 
THE ABOVE TABLES DEPICTS THERE IS SIGNIFICANT 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN  EXPERIMENTAL 
AND CONTROL GROUP 
 
TABLE NO.24 PLATELET COUNT 
 
Platelet Count: 
 
Measure: PLATELET   
group WEEKS Mean Std. 
Error 
95% Confidence Interval P 
VALUE Lower 
Bound 
Upper 
Bound 
Experiment 
1 54200 4050 46002 62398 
P<0.05 
2 53150 4018 45015 61285 
3 55150 3980 47092 63208 
4 60150 4047 51958 68342 
5 51200 3960 43183 59217 
6 45150 3882 37291 53009 
7 46150 3895 38265 54035 
8 61200 4083 52934 69466 
9 52150 3901 44252 60048 
10 47150 3907 39240 55060 
11 53150 4002 45048 61252 
68 
 
12 56150 4540 46959 65341 
13 59150 4036 50979 67321 
Control 
1 70100 4050 61902 78298 
P<0.05 
2 67950 4018 59815 76085 
3 69300 3980 61242 77358 
4 74400 4047 66208 82592 
5 65800 3960 57783 73817 
6 61350 3882 53491 69209 
7 61600 3895 53715 69485 
8 73980 4083 65714 82246 
9 66880 3901 58982 74778 
10 62330 3907 54420 70240 
11 66930 4002 58828 75032 
12 65735 4540 56544 74926 
13 72000 4036 63829 80171 
 
TABLE NO.25 PLATELET 
 
Pairwise Comparisons 
Measure: PLATELET 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
P 
VALUE 
95% Confidence Interval 
for Differenceb 
Lower 
Bound 
Upper 
Bound 
Experime
nt Control -14173.458
*
 5571.545 .15 -25452.460 -2894.455 
Control Experime
nt 14173.458
*
 5571.545 .15 2894.455 25452.460 
Based on estimated marginal means 
*. The mean difference is significant at the .05 level. 
b. Adjustment for multiple comparisons: Least Significant Difference 
(equivalent to no adjustments). 
THE ABOVE TABLES DEPICTS THERE IS NO SIGNIFICANT 
DIFFERENCE BETWEEN WEEKS AND EXPERIMENTAL AND 
CONTROL GROUP 
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TABLE NO.26 BLOOD UREA 
 
Blood Urea: 
 
4. group * WEEKS 
Measure: UREA_ 
group WEEK
S 
Mean Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Experi
ment 
P<
0.0
5 
1 52.350 2.590 47.107 57.593 
2 43.650 1.947 39.708 47.592 
3 45.200 1.966 41.221 49.179 
4 42.700 1.591 39.480 45.920 
5 38.750 1.546 35.620 41.880 
6 40.550 1.766 36.975 44.125 
7 42.800 1.464 39.837 45.763 
8 44.250 1.815 40.575 47.925 
9 40.700 1.788 37.081 44.319 
10 41.300 1.659 37.942 44.658 
11 41.000 1.707 37.544 44.456 
12 43.300 1.879 39.495 47.105 
13 38.450 1.583 35.246 41.654 
Contro
l 
P<
0.0
5 
1 48.200 2.590 42.957 53.443 
2 40.400 1.947 36.458 44.342 
3 42.950 1.966 38.971 46.929 
4 41.350 1.591 38.130 44.570 
5 41.850 1.546 38.720 44.980 
6 43.100 1.766 39.525 46.675 
7 40.500 1.464 37.537 43.463 
8 42.150 1.815 38.475 45.825 
9 43.550 1.788 39.931 47.169 
10 43.050 1.659 39.692 46.408 
11 41.050 1.707 37.594 44.506 
12 41.700 1.879 37.895 45.505 
13 40.500 1.583 37.296 43.704 
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TABLE NO.27 UREA 
 
Pairwise Comparisons 
Measure: UREA_ 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.a 95% Confidence Interval 
for Differencea 
Lower 
Bound 
Upper 
Bound 
Experime
nt Control .358 .803 .658 -1.267 1.983 
Control Experime
nt -.358 .803 .658 -1.983 1.267 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference 
(equivalent to no adjustments). 
THE ABOVE TABLES DEPICTS THERE IS SIGNGICANCE 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN  EXPERIMENTAL 
AND CONTROL GROUP 
 
TABLE NO.28 SERUM CREATINE 
Serum Creatine : 
 
4. group * WEEKS 
Measure: creatine_ 
group  WEEK
S 
Mean Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Experi
ment 
p>
0.0
5 
1 1.23 .058 1.117 1.353 
2 1.21 .034 1.143 1.278 
3 1.19 .035 1.126 1.269 
4 1.22 .035 1.159 1.300 
5 1.27 .035 1.207 1.350 
6 1.21 .041 1.137 1.302 
7 1.17 .045 1.086 1.270 
8 1.20 .047 1.112 1.301 
9 1.18 .052 1.078 1.289 
10 1.24 .034 1.179 1.315 
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11 1.26 .033 1.199 1.332 
12 1.21 .037 1.144 1.292 
13 1.23 .034 1.165 1.301 
Contro
l 
p>
0.0
5 
1 1.04 .058 .922 1.158 
2 1.21 .034 1.143 1.279 
3 1.27 .035 1.203 1.346 
4 1.19 .035 1.120 1.261 
5 1.26 .035 1.193 1.336 
6 1.25 .041 1.167 1.332 
7 1.24 .045 1.152 1.336 
8 1.24 .047 1.153 1.341 
9 1.22 .052 1.115 1.325 
10 1.22 .034 1.154 1.290 
11 1.19 .033 1.132 1.264 
12 1.25 .037 1.185 1.333 
13 1.22 .034 1.159 1.296 
 
THE ABOVE TABLES DEPICTS THERE IS no SIGNIFICANCE 
DIFFERENCE BETWEEN WEEKS EXPERIMENTAL AND CONTROL 
GROUP 
 
TABLE NO.29 SODIUM 
4. group * WEEKS 
Measure: sodium_ 
group WEEK
S 
Mean Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Experime
nt 
1 133.600 1.464 130.636 136.564 
2 131.900 .683 130.517 133.283 
3 132.400 .710 130.962 133.838 
4 130.700 .780 129.122 132.278 
5 131.750 .732 130.269 133.231 
6 130.450 .748 128.937 131.963 
7 132.400 .678 131.027 133.773 
8 130.350 .729 128.873 131.827 
9 132.700 .746 131.191 134.209 
10 131.700 .657 130.370 133.030 
11 133.000 .604 131.778 134.222 
12 132.750 .804 131.123 134.377 
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13 132.600 .763 131.054 134.146 
Control 
1 135.300 1.464 132.336 138.264 
2 131.600 .683 130.217 132.983 
3 132.150 .710 130.712 133.588 
4 130.750 .780 129.172 132.328 
5 131.500 .732 130.019 132.981 
6 132.250 .748 130.737 133.763 
7 132.850 .678 131.477 134.223 
8 132.750 .729 131.273 134.227 
9 132.300 .746 130.791 133.809 
10 131.900 .657 130.570 133.230 
11 132.050 .604 130.828 133.272 
12 131.950 .804 130.323 133.577 
13 131.700 .763 130.154 133.246 
 
TABLE NO.30 SODIUM 
 
Pairwise Comparisons 
Measure: sodium_ 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.a 95% Confidence Interval 
for Differencea 
Lower 
Bound 
Upper 
Bound 
Experime
nt Control -.212 .334 .530 -.888 .465 
Control Experime
nt .212 .334 .530 -.465 .888 
Based on estimated marginal means 
a. Adjustment for multiple comparisons: Least Significant Difference 
(equivalent to no adjustments). 
THE ABOVE TABLES DEPICTS THERE IS SIGNIFICANCE 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN  EXPERIMENTAL 
AND CONTROL GROUP 
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TABLE NO.31 POTASSIUM 
 
Potassium:  
4. group * WEEKS 
Measure: potassium_ 
group WEEK
S 
Mean Std. 
Error 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Experimen
t 
1 5.42 1.333 2.722 8.118 
2 3.43 .165 3.099 3.766 
3 3.43 .159 3.108 3.752 
4 3.45 .152 3.148 3.763 
5 3.56 .145 3.274 3.861 
6 3.55 .158 3.233 3.874 
7 3.43 .136 3.159 3.709 
8 3.58 .159 3.264 3.909 
9 3.65 .136 3.379 3.931 
10 3.57 .152 3.267 3.882 
11 3.52 .135 3.249 3.796 
12 3.50 .213 3.072 3.933 
13 3.33 .144 3.047 3.630 
Control 
1 3.76 1.333 1.067 6.463 
2 3.65 .165 3.321 3.988 
3 3.62 .159 3.303 3.947 
4 3.92 .152 3.621 4.236 
5 3.58 .145 3.290 3.878 
6 3.59 .158 3.273 3.914 
7 3.71 .136 3.436 3.987 
8 3.56 .159 3.244 3.889 
9 3.41 .136 3.139 3.690 
10 3.35 .152 3.048 3.662 
11 3.48 .135 3.209 3.756 
12 3.58 .213 3.150 4.011 
13 3.40 .144 3.116 3.698 
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TABLE NO.32 POTASSIUM 
 
Pairwise Comparisons 
 
Measure: potassium_ 
(I) group (J) group Mean 
Difference 
(I-J) 
Std. 
Error 
Sig.a 95% Confidence Interval 
for Differencea 
 
Lower 
Bound 
Upper 
Bound 
Experimen
t Control .062 .149 .681 -.240 .363 
Control Experime
nt -.062 .149 .681 -.363 .240 
THE ABOVE TABLES DEPICTS THERE IS SIGNIFICANCE 
DIFFERENCE BETWEEN WEEKS . BUT NOT IN  EXPERIMENTAL 
AND CONTROL GROUP 
 
 
TABLE NO.33 ENDOSCOPY 
 
Endoscopic findings: At Admission: 
 
 
Crosstab 
Count 
 UPPER_GI_ENDOSCOPY Total 
GRADE 1 
EV 
GRADE 2 
EV 
GRADE 3 
EV 
group 
Experime
nt 0 15 5 20 
Control 1 15 4 20 
Total 1 30 9 40 
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After 12 weeks: 
TABLE NO.34 ENDOSCOPY 
 
Crosstab 
Count 
 UGI_ENDOSCOPY_WEEK_12 Total 
GRADE 1 
EV 
GRADE 2 
EV 
GRADE 3 
EV 
group 
Experime
nt 0 15 5 20 
Control 1 14 5 20 
Total 1 29 10 40 
 
 
TABLE NO.35 CAUSE OF ACUTE EPISODE 
 
 
Cause of Current Acute episode: 
 
Crosstab 
Count 
 CAUSE_OF_HEPATITI
S 
Total 
ALCOHOL 
INTAKE 
Portal Vein 
Thrombosis 
group 
Experime
nt 18 2 20 
Control 18 2 20 
Total 36 4 40 
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TABLE NO.36 GLYCEMIC PROFILE 
 
Glycemic profile: 
Crosstab 
Count 
 GLYCAEMIC_PR
OFILE 
Total 
ABNOR
MAL 
NORM
AL 
group 
Experime
nt 0 20 20 
Control 0 20 20 
Total 0 40 40 
 
 
 
For this data the following statistical analysis was used 
Repeated measures Anova (comparisons of 13 weeks with 2 groups) 
Independent t test for compare 2 groups for age (Experiment and 
Control) 
  
  
 
 
DISCUSSION 
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DISCUSSION 
 A total of forty patients suffering from Acute on Chronic Alcohol 
Liver disease were randomised and chosen, and divided into equal test and 
control arms for Betaine therapy. They were subjected to twelve weeks of 
therapy and weekly tests were taken to assess parameters and their pattern 
of change.  
Age distribution: Out of forty patients, Five patients ranged from 36-
44 ( three in the test arm and two in the control), twelve patients between 
45-54 (5 in test and 7 in control), twenty two patients between 55-64 
(twelve in test arm and ten in control); and one patient aged 68 in the control 
arm. 
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CHART NO. 1 AGE 
 
 
Sex:  
 Thirty nine males and one female made up the sample set for this 
study. The one female was randomly entered into the test arm. There is a 
definite decreased incidence of alcoholic liver disease amongst women in 
India due to social taboos about alcohol consumption as well as about 
revealing an illness related to alcohol consumption. The subject in question 
was well within the statistically representative realms of her group and in no 
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was statistically significantly different from other members of her group in 
terms of presentation or parameters at the time of entry into study or in 
terms of response to her designated therapy compared to other members of 
her group.  
Liver Function Tests:  
 Liver function tests of all forty subjects were taken at the time of 
admission and every week for twelve weeks. Significant differences were 
found only between values of different weeks of the same patients but not 
between patients in the test arm and control arm. Many patients both in test 
and control experienced a statistically significant increase in liver enzymes 
and a ‘rehepatitis’ during the period of study in their liver enzymes. Nine 
Subjects (5, 6, 14, 17, 27, 33, 34, 38 and 39) experienced a rehepatitis – four 
in the test and five in the control arm- at 3 weeks. Seven Subjects (4, 6, 8, 9, 
10, 11, 37) –six in the test, and one in control arm-experienced a rehepatitis 
at 4 weeks. Ten subjects (15, 17, 18, 28, 29, 30, 33, 34, 38, 39) – 3 in the 
test arm, seven in the control - had a rehepatitis within three weeks of study. 
One patient (subject 26) –control arm-had a persistent hepatitis that lasted 
for 4 weeks. Two patients (7,35) - one each in the test and control arm- had 
a rehepatitis at 5 weeks. Two patients (14,24) - one each in the test and 
control arm- had a rehepatitis at week 10. One patient (28) had a rehepatitis 
at week 11. Patterns of SGOT and SGPT were consistent with each other 
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and no discrepancy was found between them. There was no change in 
alkaline phosphatase or total protein levels between different groups. 
Additionally, amongst the samples, there was no intersubject or interweek 
variation in the serum albumin levels either. Predictably the enzyme levels 
stayed within the realms of alcoholic hepatitis range with the SGOT zenith 
reaching 500. Also the bilirubin levels were statistically similar in both 
arms, and the increase in levels occurring expectedly just after the spike in 
enzyme levels. Patients only complained of a mild Gastrointestinal upset 
after consumption of the drug, which was comparable with placebo. No 
other side effects was reported. Four patients 2 in test and control each had 
Portal vein thrombosis as the cause for acute decompensation. The rest had 
continues alcohol intake as the cause. 
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CHART NO. 2  
 
 
SGOT in test group 
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Coagulogram:  
 There was no statistically significant difference in the INR alues 
between test and control arms indicating that the drug had no significant 
positive impact on the synthetic function of the inflamed liver.  
Other tests:  
 There was no significant difference found in the renal founction test 
results between different groups. Many patients were mildly hyponatremic 
or hypokalemic probably due to volume overloaded status as the study 
includes only those who have objective evidence of pre-existing alcoholic 
chronic liver disease. Most patients also developed a mild pre-renal failure 
with a moderately elevated urea and only a slightly elevated creatine level 
concomitantly with liver decompensation and hepatitis, but recovered with 
recovery of liver function. Haemoglobin levels varied between different 
patients and between different weeks of the same patient but there was no 
significant difference between the two groups due to satisfactory 
randomization. The profile of other aspects of the complete blood count was 
similar. All patients remained euglycemic throughout the trial. Endoscopy 
results did not reveal any significant downgrading of variceal grade post 
therapy. Of the 20 test subjects in the test arm, 15 had grade 2 varices and 5 
had grade 3, which continued to be the same post trial. In the control arm, 
one patient had grade 1 varices, 15 had grade 2 and 4 had grade 3; and post 
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trial only one of them had worsened- with one subject who had grade 2 
progressing to grade 3. The cause for hepatitis was all-inclusive with 
patients needing to have only their chronic liver disease attributable to 
alcohol. In the study most patients (36 in total) had the acute episode due to 
alcohol consumption-18 in each arm- whereas the only other cause of acute 
hepatitis in the sample of study was portal vein thrombosis with four 
patients suffering from it – two in each arm. 
 
  
  
 
 
CONCLUSION 
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CONCLUSION 
 Betaine Therapy had no significant effect on acute on chronic 
alcoholic liver disease. There was no statistically significant reduction in the 
number of hepatitis episodes nor in the severity of the current episodes at 
the start of the period of study. Many patients in the test arm were found to 
have liver enzyme levels the same as or even more than what they were 
before the period of study. The drug has been tried out in two of the most 
common reasons for acute flares in chronic liver disease due to alcohol and 
yet failed to produce an impact. Thus the drug which has interested so many 
in the field of non alcoholic liver disease has been no better than placebo in 
the case of alcoholic liver disease. Since dosing has not been optimised, 
further studies will be required. 
  
  
 
 
LIMITATIONS 
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LIMITATIONS 
 A major limitation of this study is the lack of clear optimal dose to 
obtain adequate efficacy of the drug. All protocols of trials involving 
betaine therapy use drug dosing based on the regimen used for 
homocystinuria. It is yet unclear if this is an over-, under- or correct dosage 
to test out. Another limitation is the number of patients. A larger sample set 
would probably be more appropriate to investigate. Thirdly, there is no 
correct consensus on the duration of therapy required. Perhaps a much 
longer trial would be required.  
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ANNEXURES 
  
“BETAINE THERAPY AND ITS INFLUENCE ON OUTCOME OF 
ACUTE ON CHRONIC ALCOHOLIC LIVER DISEASE ” 
 
PROFORMA 
 
Name:      Age/Sex: 
Address:      Occupation: 
 
SYMPTOMS: 
 
Jaundice 
Altered sensorium 
Upper GI bleed 
Coagulopathy  
Fever 
 
PAST HISTORY: 
COPD  
CVA  
CKD  
HYPOTYHROIDISM  
DIABETES MELLITUS  
VIRAL HEPATITIS  
 
PERSONAL HISTORY: 
SMOKING 
ALCOHOL 
 
GENERAL EXAMINATION: 
 
GCS  
 
 
VITAL SIGNS: 
       PR- 
       BP- 
       RR- 
 
SYSTEMIC  EXAMINATION: 
 
CVS: 
 
RS: 
 
ABDOMEN: 
 
CNS: 
 
INVESTIGATIONS: 
 
COMPLETE  HEMOGRAM 
 
RFT 
SERUM  ELECROLYTES 
LFT 
 
COAGULOGRAM 
GLYCEMIC PROFILE 
VIRAL HEPATITIS MARKERS 
 
 
ENDOSCOPIC FINDINGS 
 
 
INFORMATION SHEET 
We are conducting a study on “BETAINE THERAPY AND ITS 
INFLUENCE ON OUTCOME OF ACUTE ON CHRONIC ALCOHOLIC 
LIVER DISEASE” : among patients attending Rajiv Gandhi Government 
General Hospital, Chennai and for that your specimen may be valuable to us. 
 
           The purpose of this study is To study the BETAINE THERAPY AND 
ITS INFLUENCE ON OUTCOME OF ACUTE ON CHRONIC ALCOHOLIC 
LIVER DISEASE  
 
The privacy of the patients in the research will be maintained throughout 
the study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
 
Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not result 
in any loss of benefits to which you are otherwise entitled. 
 
The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment.  
 
The process of dividing patients who are selected will be random and it 
shall not be determined prior or during study, which group the patient is on. 
The sanctity of single blinding shall be maintained. The patient may be 
ascribed to the placebo group whereby he or she may be denied any benefit or 
harm the drug may or may not induce. 
 
The patient must wilfully accept any known side effects of the drug if he 
or she is taking so. 
 
 
Signature of Investigator    Signature of Participant 
 
Date : 
Place : 
 
 
PATIENT CONSENT FORM 
Study Detail : “BETAINE THERAPY AND ITS INFLUENCE ON 
OUTCOME OF ACUTE ON CHRONIC ALCOHOLIC 
LIVER DISEASE ” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction.  
b) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected.  
c) I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
current study and any further research that may be conducted in relation to 
it, even if I withdraw from the study I agree to this access. However, I 
understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this study.  
d) I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms.  
e) I hereby consent to participate in this study.  
f) I hereby give permission to undergo detailed clinical examination and 
blood investigations as required.  
 
Signature/thumb impression 
 
 
Patient’s Name and Address:                                   Signature of Investigator 
 
Study Investigator’s Name: 
Dr. VENKATAKRISHNAN R. 
  
  
  
 
 
 
  
  
 
  
 
 
 
 
MASTER CHART 
 
PATIENT Parameters ADMISSION WEEK 1 WEEK 2 WEEK 3 WEEK 4 WEEK 5 WEEK 6 WEEK 7 WEEK 8 WEEK 9 WEEK 10 WEEK 11 WEEK 12
AGE 62 62 62 62 62 62 62 62 62 62 62 62 62
SEX M M M M M M M M M M M M M
PLATELET COUNT 46000 48000 50000 55000 46000 40000 41000 56000 47000 42000 48000 51000 54000
HB 8.7 8.6 8.1 8.4 8.2 8.7 8 7.9 8.4 7.6 7.7 7.3 7.5
PCV 26 25 26 21 24 25 22 23 27 22 22 20 25
TC (in thousands) 7.3 10.3 7.4 6.3 11.0 5.2 7.5 5.3 10.5 5.0 10.4 10.0 8.8
UREA 56 48 44 37 36 39 41 49 45 26 43 31 36
CREATINE 1.5 1.2 1.1 1.5 1.4 0.9 0.7 0.8 0.6 1.2 1.6 1.1 0.9
SODIUM 128 130 130 126 128 122 136 127 131 129 133 135 129
POTASSIUM 2.4 2.6 3.2 3.1 3.7 3.5 3 3.5 3.5 3.5 2.9 3.6 3.1
T.BILIRUBIN 11 12.0 12.9 11.0 11.1 6.2 7.7 7.9 5.7 2.2 1.9 2.3 3.2
D.BILIRUBIN 1.9 2.9 3.7 4.0 2.1 3.6 2.5 3.5 3.5 1.2 1.5 1.1 2.2
OT 444 437 363 266 237 199 178 194 185 56 56 70 68
PT 201 179 186 153 174 135 119 108 115 62 61 60 59
ALP 54 69 70 58 68 62 63 58 54 53 69 65 59
T.PROTEIN 5.5 5.4 5.0 5.4 5.5 5.3 5.5 4.9 5.2 5.4 5.0 5.2 5.6
S.ALBUMIN 2,7 2.6 2.7 2.6 2.8 2.7 2.8 2.4 2.5 2.7 2.6 2.7 2.8
INR 3.3 3.3 3.2 2.3 1.7 2.2 2.0 1.9 1.8 1.3 1.4 1.3 1.4
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE Normal NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 3 EV GRADE 3 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 37 37 37 37 37 37 37 37 37 37 37 37 37
SEX M M M M M M M M M M M M M
PLATELET COUNT 52000 51000 53000 58000 49000 43000 44000 59000 50000 45000 51000 54000 57000
HB 8.9 9.1 8.4 8.7 8.5 9 8.3 8.2 8.7 7.9 8 7.3 7.5
PCV 26 27 25 23 21 25 21 23 24 26 21 24 20
TC (in thousands) 5.9 4.7 5.4 10.3 7.1 9.9 6.2 8.2 7.3 8.2 6.4 5.0 10.9
UREA 61 53 49 42 41 44 46 54 50 31 48 36 41
CREATINE 1.4 0.9 0.8 1.2 1.6 0.6 0.4 0.5 0.3 0.9 1.3 0.8 0.9
SODIUM 134 131 131 127 129 123 137 128 132 130 134 136 129
POTASSIUM 4.2 3 3.6 3.5 4.1 3.9 3.4 3.9 3.9 3.9 3.3 4 3.5
T.BILIRUBIN 14.6 12.2 11.5 12.7 11.7 7.3 5.9 6.3 7.8 3.8 2.1 2.1 3.0
D.BILIRUBIN 3.5 2.7 3.6 3.9 4.0 3.4 3.9 3.1 2.5 1.7 1.1 0.6 2.0
OT 462 484 323 298 202 187 196 193 195 59 61 60 74
PT 188 162 182 199 174 114 114 115 128 77 40 60 69
ALP 66 50 65 50 67 70 62 66 70 59 61 50 59
T.PROTEIN 5.2 5.0 5.5 5.3 5.6 5.5 5.3 5.0 4.8 5.0 4.8 5.5 5.2
S.ALBUMIN 2.6 2.4 2.6 2.7 2.5 2.6 2.4 2.5 2.6 2.5 2.5 2.6 2.5
INR 4.1 3.3 3.3 1.9 1.6 2.1 1.6 2.1 2.4 1.8 2.0 2.2 2.4
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 45 45 45 45 45 45 45 45 45 45 45 45 45
SEX M M M M M M M M M M M M M
PLATELET COUNT 51000 47000 49000 54000 45000 39000 40000 55000 46000 41000 47000 50000 53000
HB 7.6 7.8 8.1 8.4 8.2 8.7 8 7.9 8.4 7.6 7.7 7.3 7.5
PCV 24 22 24 22 24 22 22 26 25 23 24 25 27
TC (in thousands) 9.9 8.2 8.5 6.9 7.7 9.4 6.3 8.9 7.9 7.9 10.0 11.0 7.4
UREA 44 33 53 33 35 33 33 40 39 40 33 42 38
CREATINE 1.2 1.1 1.4 1.4 1.3 1.5 1.1 1.0 1.3 1.2 1.2 1.1 1.5
SODIUM 135 131 136 131 134 129 131 131 130 130 132 134 133
POTASSIUM 3.2 4.4 4.8 2.8 4.4 4.7 3.4 2.5 2.7 4.0 4.0 3.1 3.0
T.BILIRUBIN 11.3 13.4 11.8 11.5 10.0 6.6 7.1 7.8 5.1 3.1 2.6 3.3 3.3
D.BILIRUBIN 4.1 3.1 2.9 3.9 2.1 3.1 3.8 2.8 2.7 1.4 0.7 2.0 2.0
OT 385 272 326 266 251 187 176 200 193 50 56 62 55
PT 191 172 164 157 147 128 105 133 121 66 82 79 90
ALP 60 70 50 63 57 63 57 70 66 60 54 57 51
T.PROTEIN 5.4 5.2 5.5 4.9 5.3 5.6 5.1 5.2 4.8 5.5 5.0 4.8 5.4
S.ALBUMIN 2.6 2.7 2.7 2.5 2.8 2.8 2.6 2.7 2.7 2.7 2.4 2.6 2.5
INR 3,4 3.1 3.8 1.6 1.6 2.1 1.7 1.9 2.3 2.1 2.0 2.2 2.0
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
SUBJECT 1
SUBJECT 2
SUBJECT 3
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 63 63 63 63 63 63 63 63 63 63 63 63 63
SEX M M M M M M M M M M M M M
PLATELET COUNT 55000 53000 55000 60000 51000 45000 46000 61000 52000 47000 53000 56000 59000
HB 8.1 7.7 7.2 7.5 7.3 7.8 7.1 7 7.5 6.7 6.8 6.4 6.6
PCV 25 20 24 25 20 24 21 23 26 24 22 25 20
TC (in thousands) 10.1 5.8 8.5 10.7 4.2 6.1 10.6 7.5 7.8 7.4 7.3 10.8 9.8
UREA 55 37 31 42 36 54 49 52 44 30 34 34 30
CREATINE 1.6 1.3 1.1 1.4 1.4 1.0 1.1 1.2 1.4 1.4 1.0 1.0 1.4
SODIUM 128 132 128 127 135 132 135 128 129 127 134 137 129
POTASSIUM 2.6 4.1 2.8 3.8 3.6 4.1 4.1 3.9 3.7 3.6 4.0 4.1 2.4
T.BILIRUBIN 9.1 12.5 13.5 11.7 13.5 18.1 13.4 8.6 5.1 3.0 3.0 2.4 3.5
D.BILIRUBIN 2.6 3.9 3.4 3.4 3.9 10.0 3.4 3.3 2.4 1.6 1.8 0.7 1.4
OT 425 461 365 361 475 389 200 183 181 59 50 62 66
PT 199 174 168 196 257 243 147 123 147 64 91 54 65
ALP 64 61 61 64 55 57 70 50 52 51 57 70 55
T.PROTEIN 5.1 5.0 5.2 5.1 5.6 4.8 5.6 5.6 4.8 5.0 5.0 5.2 5.0
S.ALBUMIN 2.4 2.5 2.6 2.5 2.6 2.6 2.7 2.7 2.8 2.7 2.5 2.6 2.7
INR 4.5 4.0 3.4 1.5 3.9 3.1 2.2 1.6 2.0 1.6 2.3 2.4 1.9
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS Portal Vein Thrombosis Portal Vein Thrombosis Portal Vein ThrombosisPortal Vein ThrombosisPortal Vein ThrombosisPortal Vein ThrombosisPortal Vein ThrombosisPortal Vein ThrombosisPortal Vein Thrombosis Portal Vein ThrombosisPortal Vein ThrombosisPortal Vein Thrombosis Portal Vein Thrombosis
AGE 55 55 55 55 55 55 55 55 55 55 55 55 55
SEX M M M M M M M M M M M M M
PLATELET COUNT 52000 57000 59000 64000 55000 49000 50000 65000 56000 51000 57000 60000 63000
HB 8.5 8.8 8.3 8.6 8.4 8.9 8.2 8.1 8.6 7.8 7.9 7.5 7.7
PCV 26 27 22 25 21 25 22 24 23 22 24 26 21
TC (in thousands) 9.2 8.6 9.4 5.8 7.1 4.6 6.9 6.1 7.9 6.0 5.3 9.6 9.1
UREA 58 41 48 36 33 46 48 52 39 45 32 47 33
CREATINE 1.4 1.3 1.1 1.1 1.1 1.2 1.2 1.1 1.1 1.1 1.3 1.4 1.2
SODIUM 132 136 135 135 130 134 128 131 133 129 131 133 132
POTASSIUM 2.8 4.3 4.5 2.7 2.5 3.6 4.2 4.6 3.3 4.4 3.8 2.6 3.3
T.BILIRUBIN 15.1 11.6 11.5 11.0 13.9 5.5 5.7 6.1 6.7 2.1 3.9 3.8 3.4
D.BILIRUBIN 4.1 3.8 3.7 3.4 2.6 4.0 3.6 2.9 3.2 0.2 1.0 1.3 1.3
OT 451 324 328 499 275 197 180 195 196 65 62 56 53
PT 166 197 172 165 157 124 126 100 139 58 86 60 50
ALP 60 63 57 52 58 63 59 59 53 63 58 56 52
T.PROTEIN 5.6 5.5 5.3 5.2 4.8 4.9 5.3 5.0 5.0 5.0 5.5 5.3 5.1
S.ALBUMIN 2.4 2.5 2.5 2.7 2.5 2.6 2.6 2.5 2.4 2.5 2.6 2.6 2.5
INR 4.9 3.1 3.2 1.8 1.7 1.6 2.4 2.0 1.6 1.9 1.8 2.0 1.7
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 57 57 57 57 57 57 57 57 57 57 57 57 57
SEX M M M M M M M M M M M M M
PLATELET COUNT 46000 42000 44000 49000 40000 34000 35000 50000 41000 36000 42000 45000 48000
HB 8.4 8.2 7.7 8 7.8 8.3 7.6 7.5 8 7.2 7.3 6.9 7.1
PCV 25 27 25 25 21 21 25 23 21 24 22 19 27
TC (in thousands) 13.1 5.2 9.0 7.6 8.8 5.5 6.1 4.4 10.7 6.7 8.5 5.2 5.3
UREA 84 35 39 36 50 37 39 50 41 49 43 51 34
CREATINE 1.1 1.3 1.4 1.0 1.3 1.4 1.3 1.0 1.3 1.2 1.3 1.3 1.1
SODIUM 130 129 135 133 129 132 136 127 134 128 130 128 127
POTASSIUM 3.2 3.0 3.5 3.4 4.7 3.4 2.8 3.5 3.8 3.2 3.7 3.0 3.2
T.BILIRUBIN 18.2 11.7 11.8 13.6 13.2 6.9 6.7 7.5 6.8 3.9 2.5 3.4 2.7
D.BILIRUBIN 4.4 2.9 3.2 3.7 2.9 3.2 2.4 2.1 2.4 2.9 1.9 0.8 1.1
OT 492 385 276 326 351 193 179 177 175 75 54 62 55
PT 252 171 156 161 151 100 141 128 131 82 62 99 77
ALP 80 54 52 51 53 61 58 57 67 55 70 69 58
T.PROTEIN 5.9 5.0 5.4 5.1 5.6 5.2 5.1 5.1 5.3 5.4 4.9 5.4 5.1
SUBJECT 4
SUBJECT 5
SUBJECT 6
S.ALBUMIN 2.4 2.5 2.7 2.6 2.8 2.8 2.4 2.6 2.4 2.5 2.5 2.6 2.7
INR 4.8 3.9 3.1 1.9 2.4 2.1 1.6 2.4 2.4 1.6 2.2 1.7 2.0
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 63 63 63 63 63 63 63 63 63 63 63 63 63
SEX M M M M M M M M M M M M M
PLATELET COUNT 55000 45000 47000 52000 43000 37000 38000 53000 44000 39000 45000 48000 51000
HB 8.3 8 7.5 7.8 7.6 8.1 7.4 7.3 7.8 7 7.1 6.7 6.9
PCV 29 20 24 24 24 23 27 26 24 21 20 25 24
TC (in thousands) 16.1 7.9 9.6 7.9 7.4 6.4 11.0 5.8 9.8 9.9 4.2 6.4 6.5
UREA 51 55 39 36 33 39 42 47 45 44 31 42 49
CREATINE 1.8 1.5 1.1 1.4 1.4 1.4 1.3 1.3 1.5 1.4 1.4 1.0 1.3
SODIUM 126 130 131 127 131 136 135 137 136 132 135 128 136
POTASSIUM 4.4 2.7 3.1 2.5 3.0 3.1 3.7 2.9 3.7 2.7 3.0 3.7 2.4
T.BILIRUBIN 14.4 12.9 12.3 13.1 13.7 7.6 7.5 7.4 7.4 3.1 3.1 2.1 3.8
D.BILIRUBIN 4.6 3.4 2.6 2.2 3.4 3.9 3.6 3.0 2.9 0.9 1.7 0.4 2.5
OT 381 261 256 338 383 193 179 180 185 56 59 55 73
PT 141 195 181 169 162 117 134 140 104 73 88 90 97
ALP 68 62 66 66 52 55 59 68 60 70 62 54 68
T.PROTEIN 5.9 5.6 5.0 5.4 5.2 5.2 5.5 5.3 5.2 5.5 5.6 4.8 5.4
S.ALBUMIN 2.6 2.5 2.6 2.6 2.5 2.5 2.6 2.6 2.5 2.7 2.5 2.6 2.4
INR 3.8 3.5 4.1 1.9 2.2 2.0 2.0 2.3 1.7 1.9 2.1 1.8 1.8
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 60 60 60 60 60 60 60 60 60 60 60 60 60
SEX M M M M M M M M M M M M M
PLATELET COUNT 58000 51000 53000 58000 49000 43000 44000 59000 50000 45000 51000 54000 57000
HB 8.7 8.9 9.1 7.7 7.9 8.9 7.9 7.9 8.1 8.4 8.3 8.9 8.9
PCV 26 25 25 20 19 27 21 21 25 24 24 29 23
TC (in thousands) 11.4 9.2 6.5 5.3 9.9 10.2 4.5 7.9 8.4 6.8 11.0 10.2 5.2
UREA 62 35 52 30 53 45 35 44 38 52 41 54 37
CREATINE 1.5 1.4 1.5 1.3 1.5 1.4 1.0 1.3 1.2 1.2 1.4 1.4 1.2
SODIUM 132 131 134 131 135 127 128 136 133 130 135 131 132
POTASSIUM 3.6 3.1 3.1 4.6 4.0 3.9 3.8 4.1 3.7 2.4 3.2 3.3 3.6
T.BILIRUBIN 10.4 12.0 13.0 13.6 11.9 12.2 14.1 9.7 5.2 3.3 3.3 2.6 3.1
D.BILIRUBIN 2.9 3.8 2.4 2.5 3.7 3.6 3.6 2.4 3.8 1.3 1.1 1.3 1.1
OT 355 383 226 470 453 194 187 188 192 50 71 56 60
PT 173 180 200 183 156 149 138 113 112 50 76 58 74
ALP 50 59 52 66 65 65 68 61 50 62 69 50 52
T.PROTEIN 5.2 5.3 5.1 5.4 4.9 5.2 5.2 5.3 5.5 5.2 5.6 5.3 4.8
S.ALBUMIN 2.8 2.6 2.5 2.5 2.5 2.7 2.7 2.5 2.5 2.7 2.5 2.6 2.6
INR 4.3 3.8 3.7 1.8 2.0 1.9 1.8 2.0 1.9 2.2 2.3 1.8 2.2
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 58 58 58 58 58 58 58 58 58 58 58 58 58
SEX M M M M M M M M M M M M M
PLATELET COUNT 33000 38000 40000 45000 36000 30000 31000 46000 37000 32000 38000 41000 44000
HB 10 9.9 8.1 8.4 8.2 8.7 8 7.9 8.4 7.6 7.7 7.3 7.5
PCV 34 27 26 25 25 24 21 19 24 18 25 19 24
TC (in thousands) 3.7 4.9 10.9 6.4 10.9 7.6 8.4 4.6 9.9 5.3 6.5 10.5 5.5
UREA 77 32 40 50 32 37 47 45 32 38 38 31 39
CREATINE 1.2 1.1 1.0 1.3 1.5 1.0 1.2 1.5 1.4 1.0 1.1 1.1 1.2
SODIUM 146 131 128 137 136 131 129 129 137 134 131 136 137
POTASSIUM 2.4 4.4 3.3 3.3 4.2 3.8 2.6 4.4 4.4 2.7 3.2 4.7 4.0
T.BILIRUBIN 15.1 11.9 11.3 12.7 11.4 8.5 9.3 5.9 5.6 2.4 2.9 2.9 3.7
D.BILIRUBIN 6.1 3.8 2.3 3.3 3.3 2.9 3.4 3.7 2.4 1.6 1.3 1.7 2.0
OT 423 483 390 500 221 189 182 178 195 73 56 54 50
SUBJECT 7
SUBJECT 8
SUBJECT 9
PT 234 176 186 189 194 103 101 107 129 99 59 81 86
ALP 54 68 67 54 70 51 57 59 51 62 58 52 53
T.PROTEIN 5.2 5.1 5.1 5.2 5.5 4.9 5.4 4.8 5.3 5.1 5.5 5.0 5.2
S.ALBUMIN 2.5 2.6 2.5 2.5 2.6 2.4 2.7 2.7 2.5 2.5 2.6 2.6 2.5
INR 4.1 3.8 3.5 2.3 2.1 2.1 1.6 1.6 2.3 1.6 2.4 2.5 1.7
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 58 58 58 58 58 58 58 58 58 58 58 58 58
SEX M M M M M M M M M M M M M
PLATELET COUNT 59000 54000 56000 61000 52000 46000 47000 62000 53000 48000 54000 57000 60000
HB 8.3 8.9 8.4 8.7 8.5 9 8.3 8.2 8.7 7.9 8 7.6 7.8
PCV 26 25 26 26 23 26 19 19 21 26 25 21 20
TC (in thousands) 10.4 7.2 7.3 9.1 8.1 10.3 8.8 5.5 5.3 7.5 7.5 7.2 8.1
UREA 41 54 49 42 31 31 52 31 35 45 44 33 37
CREATINE 1.1 1.2 1.5 1.0 1.1 1.3 1.3 1.2 1.3 1.3 1.2 1.0 1.3
SODIUM 127 129 130 132 133 129 131 132 131 135 134 135 127
POTASSIUM 3.8 2.6 2.6 2.7 3.3 3.8 3.6 2.5 3.6 4.4 4.2 4.3 3.5
T.BILIRUBIN 16.4 12.7 12.7 12.1 12.1 15.1 5.9 7.5 7.1 2.4 2.8 2.5 2.6
D.BILIRUBIN 6.8 3.1 3.1 2.4 2.0 2.2 3.8 3.5 3.4 1.2 1.8 1.5 1.5
OT 391 281 390 240 478 181 177 193 186 73 62 55 68
PT 203 197 170 167 172 149 131 149 120 75 96 88 82
ALP 74 70 60 55 53 56 63 52 50 58 63 68 57
T.PROTEIN 5.5 5.4 5.1 5.4 4.8 4.8 5.0 5.3 4.9 5.3 4.9 5.3 5.5
S.ALBUMIN 2.6 2.6 2.6 2.6 2.8 2.6 2.7 2.8 2.7 2.6 2.4 2.7 2.7
INR 4.4 3.8 3.0 2.1 4.2 2.2 1.7 2.4 1.9 2.5 1.9 2.2 2.4
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 58 58 58 58 58 58 58 58 58 58 58 58 58
SEX M M M M M M M M M M M M M
PLATELET COUNT 51000 45000 47000 52000 43000 37000 38000 53000 44000 39000 45000 48000 51000
HB 10.1 10 9.5 9.8 9.6 10.1 9.4 9.3 9.8 9 9.1 8.7 8.9
PCV 32 24 24 27 26 30 25 28 26 23 21 22 23
TC (in thousands) 15.7 7.8 4.6 6.5 9.3 9.1 4.1 6.0 6.2 10.5 7.7 8.5 7.5
UREA 41 55 55 46 40 52 48 31 39 42 42 54 31
CREATINE 0.6 1.1 1.1 1.4 1.0 1.2 1.4 1.5 1.4 1.2 1.5 1.1 1.5
SODIUM 144 137 135 129 134 135 137 132 128 133 129 130 137
POTASSIUM 3.8 3.5 4.0 2.9 4.0 3.2 3.8 4.3 4.8 4.3 2.8 3.5 4.6
T.BILIRUBIN 15.1 13.8 13.1 13.3 12.3 7.7 5.3 5.9 6.3 2.4 3.9 3.0 2.3
D.BILIRUBIN 4.3 3.0 2.1 2.8 3.6 3.1 3.5 2.8 3.0 1.4 2.5 1.6 1.1
OT 364 273 377 429 299 198 199 195 179 60 67 72 70
PT 148 172 161 199 156 147 135 144 141 88 89 66 53
ALP 50 59 69 62 66 66 58 66 50 57 68 50 60
T.PROTEIN 5.7 5.1 5.0 5.5 5.0 5.3 5.0 5.1 5.5 5.0 5.4 5.1 5.5
S.ALBUMIN 2.4 2.7 2.4 2.7 2.5 2.6 2.6 2.6 2.5 2.7 2.6 2.8 2.7
INR 4.5 4.1 3.7 2.0 4.4 2.0 1.6 2.5 2.0 2.2 1.6 2.4 2.1
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 41 41 41 41 41 41 41 41 41 41 41 41 41
SEX M M M M M M M M M M M M M
PLATELET COUNT 30000 34000 36000 41000 32000 26000 27000 42000 33000 28000 34000 37000 40000
HB 7.5 8 7.5 7.8 7.6 8.1 7.4 7.3 7.8 7 7.1 6.7 6.9
PCV 24 27 26 18 21 21 27 21 25 22 20 26 18
TC (in thousands) 16.8 10.2 9.4 8.4 6.3 9.4 8.8 8.2 10.4 9.5 7.5 5.8 10.8
UREA 61 37 41 47 41 53 30 45 38 39 40 34 33
CREATINE 1.3 1.0 1.4 1.0 1.3 1.2 1.2 1.4 1.3 1.5 1.3 1.3 1.5
SODIUM 142 129 137 132 127 131 133 128 136 127 134 127 131
POTASSIUM 4.4 3.3 2.6 3.9 3.2 2.8 4.5 4.4 4.2 4.1 3.3 3.4 3.2
SUBJECT 10
SUBJECT 11
T.BILIRUBIN 13.5 12.8 13.4 12.9 11.7 7.7 5.0 6.3 6.7 3.2 3.2 2.8 2.5
D.BILIRUBIN 4.8 2.3 3.9 2.4 2.8 3.3 3.1 2.9 2.0 1.5 1.6 1.2 1.0
OT 441 327 243 391 285 195 182 180 185 61 75 53 68
PT 156 174 164 164 185 102 145 115 116 52 98 77 54
ALP 62 55 57 56 54 66 56 61 64 65 60 64 55
T.PROTEIN 5.3 5.0 5.1 5.4 5.3 5.5 5.5 5.5 5.5 5.3 5.4 5.5 5.4
S.ALBUMIN 2.5 2.7 2.7 2.5 2.5 2.6 2.7 2.7 2.7 2.4 2.5 2.4 2.4
INR 3.9 4.2 3.3 1.7 2.2 2.3 1.8 2.1 2.2 2.3 1.8 2.0 2.3
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 3 EV GRADE 3 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 47 47 47 47 47 47 47 47 47 47 47 47 47
SEX M M M M M M M M M M M M M
PLATELET COUNT 68000 70000 72000 77000 68000 62000 63000 78000 69000 64000 70000 73000 76000
HB 7.4 7.1 6.6 6.9 6.7 7.2 6.5 6.4 6.9 6.1 6.2 5.8 6
PCV 26 24 19 23 21 26 26 26 22 18 20 25 23
TC (in thousands) 4.1 5.5 5.3 4.8 8.8 7.3 10.4 9.4 8.1 4.1 8.4 5.8 8.3
UREA 39 42 55 45 31 41 45 55 35 53 39 53 47
CREATINE 0.7 1.2 1.4 1.5 1.1 1.4 1.2 1.4 1.2 1.2 1.5 1.3 1.2
SODIUM 135 134 134 128 128 128 135 132 133 136 133 128 130
POTASSIUM 4 3.7 3.5 4.8 2.9 4.6 4.5 4.5 3.7 3.9 2.7 2.5 3.5
T.BILIRUBIN 16.1 13.7 12.5 11.2 11.4 5.5 7.4 6.8 6.1 3.9 3.4 3.8 3.8
D.BILIRUBIN 7.1 3.5 2.3 3.7 3.7 3.0 3.3 3.5 2.2 2.6 2.1 2.8 1.8
OT 381 271 220 311 374 181 194 184 196 74 58 51 67
PT 164 198 167 167 187 150 138 127 141 83 73 59 59
ALP 64 62 69 70 68 59 63 62 54 68 65 53 51
T.PROTEIN 5.5 5.0 5.4 4.9 5.3 5.0 5.0 5.4 4.9 5.4 5.2 5.0 5.4
S.ALBUMIN 2.9 2.5 2.8 2.8 2.6 2.5 2.7 2.8 2.5 2.6 2.7 2.6 2.8
INR 3.9 3.8 3.7 2.5 2.3 1.5 1.8 1.5 1.7 1.6 1.9 2.1 2.3
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 55 55 55 55 55 55 55 55 55 55 55 55 55
SEX M M M M M M M M M M M M M
PLATELET COUNT 66000 66000 68000 73000 64000 58000 59000 74000 65000 60000 66000 69000 72000
HB 6 6.1 5.6 5.9 5.7 6.2 5.5 5.4 5.9 5.1 5.2 4.8 5
PCV 21 25 21 19 21 23 19 27 25 24 26 24 27
TC (in thousands) 13.2 9.4 7.5 4.6 10.6 4.3 10.1 7.7 5.1 7.5 7.1 10.8 5.2
UREA 41 54 54 38 47 44 44 32 55 36 39 44 53
CREATINE 1.2 1.1 1.4 1.3 1.1 1.3 1.4 1.4 1.4 1.4 1.1 1.3 1.2
SODIUM 131 127 133 127 128 136 133 129 132 137 137 132 133
POTASSIUM 4.1 2.6 4.6 3.0 3.1 3.6 2.7 4.3 4.3 3.1 3.5 3.7 3.2
T.BILIRUBIN 15.2 12.5 12.5 11.4 12.6 11.6 9.0 5.2 7.4 5.6 4.6 11.4 10.1
D.BILIRUBIN 6.3 2.5 3.6 3.5 2.7 3.3 3.8 2.3 3.5 3.6 2.5 4.6 3.3
OT 255 228 248 397 389 184 198 185 192 70 354 288 219
PT 124 155 167 150 192 143 114 102 148 60 212 161 102
ALP 90 69 58 64 63 64 70 69 66 70 66 51 70
T.PROTEIN 5.7 4.9 4.9 5.2 5.5 5.4 5.0 5.2 5.6 5.1 5.3 5.2 5.0
S.ALBUMIN 2.8 2.7 2.6 2.6 2.7 2.8 2.5 2.6 2.4 2.6 2.8 2.7 2.4
INR 4.5 3.8 4.1 1.8 1.5 2.5 1.7 2.3 2.2 1.9 2.1 1.5 2.1
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 61 61 61 61 61 61 61 61 61 61 61 61 61
SEX M M M M M M M M M M M M M
PLATELET COUNT 44000 40000 42000 47000 38000 32000 33000 48000 39000 34000 40000 43000 46000
HB 9.1 9.9 9.4 9.7 9.5 10 9.3 9.2 9.7 8.9 9 8.6 8.8
PCV 26 28 24 25 21 22 26 25 24 23 19 18 25
TC (in thousands) 11 8.6 4.6 7.8 8.1 8.4 5.0 10.0 8.5 4.2 10.4 4.2 10.1
UREA 61 55 55 49 33 31 44 32 30 31 53 53 33
SUBJECT 12
SUBJECT 13
SUBJECT 14
CREATINE 1.3 1.1 1.0 1.2 1.1 1.0 1.2 1.4 1.0 1.2 1.3 1.5 1.2
SODIUM 137 134 129 134 134 134 129 128 134 135 127 137 137
POTASSIUM 4.6 3.2 2.6 3.9 4.1 2.9 3.2 2.8 3.0 2.8 3.3 2.7 4.4
T.BILIRUBIN 14.9 12.9 12.1 12.5 13.8 7.4 5.0 7.8 6.5 3.6 3.6 3.3 2.9
D.BILIRUBIN 3.5 2.2 3.1 2.2 2.0 2.1 3.7 2.2 2.5 1.5 1.7 1.2 1.4
OT 466 265 378 437 370 191 189 198 183 75 58 69 71
PT 147 165 151 182 191 117 120 105 118 58 100 91 68
ALP 50 50 59 52 70 58 63 51 60 55 69 65 67
T.PROTEIN 5.3 5.5 5.2 5.3 5.2 5.3 5.2 5.2 5.0 4.9 5.2 5.4 5.5
S.ALBUMIN 2.7 2.4 2.6 2.4 2.8 2.7 2.5 2.7 2.7 2.4 2.4 2.5 2.8
INR 4.9 2.2 3.7 3.8 1.7 1.6 2.2 1.9 1.7 1.7 2.2 2.2 2.4
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 3 EV GRADE 3 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 52 52 52 52 52 52 52 52 52 52 52 52 52
SEX M M M M M M M M M M M M M
PLATELET COUNT 76000 81000 83000 88000 80000 73000 74000 90000 80000 75000 81000 84000 87000
HB 5.8 6.3 5.8 6.1 5.9 6.4 5.7 5.6 6.1 5.3 5.4 5 5.2
PCV 23 20 23 25 19 24 24 20 18 22 20 27 20
TC (in thousands) 12.1 5.9 6.6 5.0 9.0 7.8 9.8 4.7 4.7 6.1 4.8 6.5 9.4
UREA 41 32 34 55 40 37 46 53 32 39 36 49 50
CREATINE 1.2 1.1 1.3 1.1 1.5 1.2 1.4 1.2 1.0 1.1 1.0 1.3 1.4
SODIUM 131 128 132 127 130 129 136 134 129 134 133 132 137
POTASSIUM 4.1 3.4 3.6 4.2 2.8 3.4 3.1 3.1 3.6 3.1 4.1 2.6 2.9
T.BILIRUBIN 11.1 12.4 13.8 11.0 11.1 7.4 6.3 6.7 7.4 2.5 3.6 4.0 3.1
D.BILIRUBIN 3.5 3.3 3.9 3.6 2.2 3.0 3.2 2.6 3.1 1.5 1.1 1.1 2.0
OT 381 297 202 338 294 187 179 191 192 59 74 73 68
PT 189 183 153 164 166 110 148 103 101 83 94 59 93
ALP 55 55 63 60 63 66 58 60 70 55 53 65 68
T.PROTEIN 5.4 5.0 5.1 5.0 5.2 5.2 5.5 5.4 5.0 5.2 5.0 4.9 5.4
S.ALBUMIN 2.8 2.5 2.5 2.5 2.5 2.7 2.8 2.7 2.5 2.7 2.5 2.5 2.6
INR 4 3.0 3.3 1.9 1.9 2.3 2.3 1.5 2.2 1.9 2.2 1.9 1.5
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 62 62 62 62 62 62 62 62 62 62 62 62 62
SEX M M M M M M M M M M M M M
PLATELET COUNT 74000 72000 74000 79000 70000 64000 65000 80000 71000 66000 72000 75000 78000
HB 8.2 8.5 8 8.3 8.1 8.6 7.9 7.8 8.3 7.5 7.6 7.2 7.4
PCV 25 21 24 19 18 26 24 22 26 20 18 20 18
TC (in thousands) 12.9 4.0 9.7 9.4 7.7 6.7 7.6 8.8 4.3 5.7 5.6 7.1 8.0
UREA 44 31 39 39 42 37 43 45 37 47 46 48 30
CREATINE 0.9 1.1 1.0 1.1 1.1 1.5 1.4 1.2 1.4 1.3 1.3 1.4 1.0
SODIUM 133 135 128 135 136 134 128 131 137 129 136 137 135
POTASSIUM 4 3.2 4.8 3.1 4.6 2.4 3.4 3.4 4.2 3.9 3.5 3.9 2.9
T.BILIRUBIN 12.5 12.7 13.1 15.1 11.9 10.9 6.1 5.7 6.4 2.0 2.3 2.6 1.4
D.BILIRUBIN 3.6 2.9 2.9 3.5 2.4 2.7 3.1 3.1 2.9 1.1 1.0 0.9 1.0
OT 361 279 497 479 368 194 194 193 199 57 75 68 57
PT 171 178 171 183 189 118 111 124 127 64 87 85 63
ALP 82 54 65 70 55 61 61 62 69 65 55 52 68
T.PROTEIN 5.8 5.4 5.1 5.3 5.5 5.4 4.9 5.6 5.5 5.1 5.5 5.3 4.9
S.ALBUMIN 2.7 2.7 2.5 2.7 2.4 2.6 2.6 2.5 2.5 2.7 2.6 2.6 2.5
INR 4.1 3.1 3.3 1.6 2.2 1.6 2.5 2.0 2.0 1.7 2.4 2.1 1.8
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 44 44 44 44 44 44 44 44 44 44 44 44 44
SEX F F F F F F F F F F F F F
PLATELET COUNT 38000 36000 38000 43000 34000 28000 29000 44000 35000 30000 36000 39000 42000
HB 6.1 5.6 5.1 5.4 5.2 5.7 5 4.9 5.4 4.6 4.7 4.3 4.5
SUBJECT 15
SUBJECT 16
SUBJECT 17
PCV 24 20 19 27 18 22 18 21 21 18 18 18 26
TC (in thousands) 7.1 5.9 6.1 9.6 8.9 9.2 4.8 8.2 6.4 4.2 10.3 10.6 8.0
UREA 54 49 39 48 35 34 52 55 34 50 51 35 43
CREATINE 1.3 1.4 1.3 1.0 1.4 1.3 1.1 1.2 1.4 1.5 1.1 1.5 1.3
SODIUM 135 137 132 135 135 131 128 127 135 133 137 137 129
POTASSIUM 41 4.6 3.0 4.2 2.8 2.9 2.9 2.6 2.4 4.0 3.0 3.3 4.4
T.BILIRUBIN 13.1 11.5 12.7 15.7 11.7 14.9 6.9 7.9 7.2 3.6 3.4 3.9 2.3
D.BILIRUBIN 5.1 3.4 2.0 3.7 3.4 2.5 2.2 2.9 3.9 1.2 1.4 1.8 0.9
OT 258 236 402 428 334 175 181 178 175 69 58 64 71
PT 133 151 199 150 173 147 126 144 132 74 53 70 57
ALP 53 52 50 57 52 59 53 63 68 51 60 52 64
T.PROTEIN 5.5 5.4 5.0 5.4 5.4 5.5 4.8 5.5 5.3 5.3 5.3 4.9 5.5
S.ALBUMIN 2.6 2.5 2.7 2.5 2.7 2.4 2.7 2.6 2.7 2.5 2.5 2.7 2.6
INR 4.1 2.7 4.2 2.0 2.2 1.9 1.8 2.3 2.3 2.5 1.8 2.1 1.8
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 3 EV GRADE 3 EV
CAUSE OF HEPATITIS Portal Vein Thrombosis Portal Vein Thrombosis Portal Vein ThrombosisPortal Vein ThrombosisPortal Vein ThrombosisPortal Vein ThrombosisPortal Vein ThrombosisPortal Vein ThrombosisPortal Vein Thrombosis Portal Vein ThrombosisPortal Vein ThrombosisPortal Vein Thrombosis Portal Vein Thrombosis
AGE 47 47 47 47 47 47 47 47 47 47 47 47 47
SEX M M M M M M M M M M M M M
PLATELET COUNT 70000 72000 74000 79000 70000 64000 65000 80000 71000 66000 72000 75000 78000
HB 10.5 10.6 10.1 10.4 10.2 10.7 10 9.9 10.4 9.6 9.7 9.3 9.5
PCV 30 25 21 27 25 19 24 20 20 20 18 23 26
TC (in thousands) 7.2 9.2 7.7 6.3 8.8 8.7 5.4 9.2 5.8 9.4 9.4 5.7 8.5
UREA 35 52 54 55 43 39 42 42 54 45 53 40 44
CREATINE 1.1 1.5 1.1 1.3 1.3 1.1 1.5 1.3 1.1 1.2 1.1 1.1 1.3
SODIUM 140 135 135 127 133 129 129 128 137 132 134 131 136
POTASSIUM 4 3.8 3.0 2.9 3.7 2.6 3.1 2.6 2.9 3.0 4.7 3.6 3.3
T.BILIRUBIN 10.8 11.2 13.1 13.5 13.9 7.4 5.7 6.6 7.8 3.9 3.5 3.2 3.3
D.BILIRUBIN 4 2.0 3.0 3.1 3.1 2.1 2.4 3.5 3.8 1.9 0.9 0.9 1.8
OT 391 423 362 422 205 195 196 193 193 67 70 58 65
PT 148 161 191 164 175 124 121 127 119 86 55 99 88
ALP 76 51 70 67 64 55 62 53 65 69 60 51 60
T.PROTEIN 5.7 5.4 5.3 5.4 5.5 5.4 5.2 5.5 5.2 5.3 4.8 5.4 5.4
S.ALBUMIN 2.9 2.7 2.5 2.5 2.7 2.5 2.5 2.7 2.5 2.8 2.6 2.5 2.4
INR 4.2 3.8 3.6 2.1 2.1 1.7 2.1 2.3 2.2 1.7 1.8 1.6 2.2
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 46 46 46 46 46 46 46 46 46 46 46 46 46
SEX M M M M M M M M M M M M M
PLATELET COUNT 60000 61000 63000 68000 59000 53000 54000 69000 60000 55000 61000 64000 67000
HB 10.4 10.5 10 10.3 10.1 10.6 9.9 9.8 10.3 9.5 9.6 9.2 9.4
PCV 28 25 19 23 22 21 20 26 24 27 19 19 18
TC (in thousands) 9.7 8.7 6.9 9.4 8.1 8.3 7.6 8.4 10.2 4.6 8.2 7.6 5.5
UREA 44 43 34 48 43 38 30 31 52 44 34 55 31
CREATINE 1.3 1.3 1.0 1.1 1.1 1.4 1.2 1.2 1.0 1.5 1.3 1.2 1.0
SODIUM 128 132 135 134 130 127 134 132 127 134 131 131 136
POTASSIUM 3.2 3.1 2.5 3.6 2.8 4.6 2.9 4.0 3.8 4.5 4.2 4.4 2.4
T.BILIRUBIN 11.8 12.8 12.4 12.4 12.4 7.7 7.7 5.2 7.8 3.0 2.1 3.2 3.8
D.BILIRUBIN 5.1 3.4 3.8 2.7 3.5 3.9 3.5 3.4 3.6 1.2 0.7 1.8 1.8
OT 394 303 200 334 266 182 197 175 182 59 69 50 66
PT 111 192 157 151 160 102 120 100 101 54 60 78 95
ALP 48 57 70 50 57 56 57 70 58 59 64 65 65
T.PROTEIN 5.4 4.9 5.3 5.3 4.9 5.2 5.1 5.3 5.0 4.8 5.2 5.4 5.0
S.ALBUMIN 2.7 2.6 2.5 2.4 2.8 2.5 2.6 2.6 2.5 2.8 2.6 2.5 2.8
INR 5.3 3.4 3.7 1.6 2.5 1.6 1.6 1.6 2.3 1.7 1.8 1.6 2.5
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 3 EV GRADE 3 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 52 52 52 52 52 52 52 52 52 52 52 52 52
SUBJECT 18
SUBJECT 19
SUBJECT 20
SEX M M M M M M M M M M M M M
PLATELET COUNT 29000 28000 30000 35000 26000 20000 21000 36000 27000 22000 28000 31000 34000
HB 10 9.3 8.8 9.1 8.9 9.4 8.7 8.6 9.1 8.3 8.4 8 8.2
PCV 29 21 25 27 18 18 23 20 18 27 21 19 19
TC (in thousands) 7.5 6.4 5.4 7.1 5.6 8.4 5.4 7.9 4.9 5.0 7.3 6.7 8.2
UREA 34 32 35 47 32 44 31 49 40 34 47 32 33
CREATINE 1.1 1.2 1.1 1.0 1.4 1.1 1.1 1.1 1.1 1.0 1.3 1.5 1.4
SODIUM 141 136 135 136 129 131 131 135 137 135 129 132 130
POTASSIUM 3.4 4.5 4.2 4.4 3.8 2.6 3.3 3.8 2.7 2.7 3.2 2.6 2.9
T.BILIRUBIN 11.7 13.0 12.2 12.9 13.9 5.6 6.8 6.7 6.5 3.9 2.3 2.2 2.7
D.BILIRUBIN 4.8 2.1 2.1 3.8 3.4 2.5 2.7 3.9 3.4 1.4 0.6 0.9 1.6
OT 445 259 211 355 217 180 187 190 187 57 69 56 66
PT 122 155 200 192 177 103 114 108 110 78 57 60 67
ALP 84 70 60 68 69 60 60 69 56 65 60 69 59
T.PROTEIN 5.4 5.5 5.1 5.0 5.6 5.3 5.1 5.4 5.6 5.3 5.0 5.4 5.1
S.ALBUMIN 2.4 2.4 2.7 2.7 2.4 2.5 2.7 2.5 2.7 2.8 2.5 2.5 2.5
INR 4.1 3.2 3.5 3.9 2.1 1.7 1.8 2.4 1.9 2.3 1.8 1.6 2.0
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 3 EV GRADE 3 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 51 51 51 51 51 51 51 51 51 51 51 51 51
SEX M M M M M M M M M M M M M
PLATELET COUNT 78000 78000 80000 85000 76000 70000 71000 86000 77000 72000 78000 8100 84000
HB 7.2 6.8 6.3 6.6 6.4 6.9 6.2 6.1 6.6 5.8 5.9 5.5 5.7
PCV 24 23 23 25 25 24 22 27 26 24 26 20 20
TC (in thousands) 14.3 10.7 4.6 7.1 6.1 4.8 5.6 9.2 11.0 8.3 6.1 6.0 10.8
UREA 42 33 30 36 49 53 37 34 33 39 43 54 39
CREATINE 1.5 1.0 1.2 1.4 1.4 1.3 1.3 1.1 1.1 1.2 1.2 1.3 1.1
SODIUM 133 132 132 137 131 131 131 131 134 134 133 132 132
POTASSIUM 4.1 3.2 4.5 4.8 3.0 3.5 3.3 3.0 3.2 4.8 3.3 7.4 4.7
T.BILIRUBIN 14.4 11.6 12.9 13.6 13.6 5.2 7.5 6.8 5.5 6.5 3.4 6.8 5.1
D.BILIRUBIN 5.9 2.3 3.8 3.9 3.9 3.3 3.2 3.1 3.3 3.9 1.6 2.5 3.8
OT 419 339 204 383 207 177 178 175 194 74 260 156 51
PT 251 171 155 188 187 143 141 126 134 64 96 88 69
ALP 46 60 55 60 67 64 51 62 50 63 70 64 61
T.PROTEIN 5.1 4.8 5.5 5.6 5.5 5.2 5.4 4.9 5.3 5.3 4.9 5.2 5.3
S.ALBUMIN 2.4 2.7 2.6 2.5 2.7 2.7 2.8 2.8 2.5 2.5 2.5 2.4 2.5
INR 4.4 3.7 3.2 2.0 2.5 1.8 1.6 2.2 2.2 1.6 3.4 2.0 2.3
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 62 62 62 62 62 62 62 62 62 62 62 62 62
SEX M M M M M M M M M M M M M
PLATELET COUNT 75000 74000 76000 81000 72000 66000 67000 82000 73000 68000 74000 77000 80000
HB 9.9 10 9.5 9.8 9.6 10.1 9.4 9.3 9.8 9 9.1 8.7 8.9
PCV 34 28 28 26 31 32 25 31 28 30 26 26 25
TC (in thousands) 15 6.9 9.3 5.1 8.8 5.9 9.9 4.7 10.6 10.7 8.8 4.5 6.4
UREA 43 33 32 43 34 32 44 41 49 54 55 37 33
CREATINE 1 1.2 1.4 1.4 1.4 1.0 1.5 1.4 1.1 1.3 1.1 1.3 1.3
SODIUM 125 136 137 129 128 131 131 130 129 134 130 130 130
POTASSIUM 4.1 3.3 3.9 4.2 4.3 3.4 3.6 4.0 4.2 3.3 2.8 4.3 2.5
T.BILIRUBIN 12.9 13.4 11.2 11.6 11.7 7.6 7.0 6.7 5.1 3.0 2.7 3.6 2.2
D.BILIRUBIN 3.9 3.0 3.5 3.2 2.3 3.7 2.4 2.6 3.1 1.9 0.8 0.6 1.2
OT 425 488 439 219 254 175 197 197 188 51 51 69 66
PT 231 187 171 189 181 138 106 102 114 74 69 45 47
ALP 72 67 62 65 52 67 68 69 69 62 63 67 57
T.PROTEIN 5.2 5.0 5.0 5.0 5.1 5.0 4.9 5.3 5.3 5.2 5.0 5.0 5.5
S.ALBUMIN 2.6 2.7 2.5 2.7 2.5 2.5 2.5 2.7 2.7 2.8 2.5 2.4 2.6
INR 4.6 3.2 3.7 1.8 2.5 1.8 1.7 2.3 2.2 1.6 1.7 2.1 2.3
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
SUBJECT 21
SUBJECT 22
SUBJECT 23
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 59 59 59 59 59 59 59 59 59 59 59 59 59
SEX M M M M M M M M M M M M M
PLATELET COUNT 30000 30000 32000 37000 28000 22000 23000 38000 29999 24000 30000 33000 36000
HB 6.5 6.6 6.1 6.4 6.2 6.7 6 5.9 6.4 5.6 5.7 5.3 5.5
PCV 21 20 26 25 23 24 19 24 19 20 20 20 20
TC (in thousands) 12.1 10.3 4.7 8.9 10.0 8.5 10.4 4.8 10.9 5.8 8.5 6.5 7.8
UREA 47 55 34 42 43 45 38 45 30 34 39 33 33
CREATINE 1.3 1.2 1.2 1.2 1.1 1.1 1.3 1.3 1.3 1.0 1.2 1.1 1.4
SODIUM 126 135 129 129 132 133 135 127 127 129 129 136 129
POTASSIUM 2.4 4.4 3.6 3.3 3.8 2.7 2.6 4.5 2.5 3.4 3.1 3.4 3.6
T.BILIRUBIN 18.1 11.5 13.3 14.0 13.9 14.5 5.7 5.3 6.6 3.4 2.1 3.0 2.7
D.BILIRUBIN 7.7 3.7 2.7 3.7 3.3 5.3 3.2 2.8 3.0 2.3 1.0 1.1 1.4
OT 404 343 237 202 490 185 180 190 194 68 58 70 71
PT 145 183 155 182 151 103 125 121 137 68 90 86 91
ALP 48 68 51 69 65 54 57 63 68 51 68 66 66
T.PROTEIN 5.2 4.9 5.1 5.0 5.0 5.0 5.1 5.6 5.2 5.0 4.9 5.5 5.1
S.ALBUMIN 2.5 2.4 2.8 2.8 2.6 2.8 2.5 2.5 2.8 2.6 2.4 2.6 2.7
INR 4.4 4.0 3.7 1.9 2.2 3.9 2.1 2.3 2.1 1.6 1.5 1.6 1.7
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 3 EV GRADE 3 EV
CAUSE OF HEPATITIS Portal Vein Thrombosis Portal Vein Thrombosis Portal Vein ThrombosisPortal Vein ThrombosisPortal Vein ThrombosisPortal Vein ThrombosisPortal Vein ThrombosisPortal Vein ThrombosisPortal Vein Thrombosis Portal Vein ThrombosisPortal Vein ThrombosisPortal Vein Thrombosis Portal Vein Thrombosis
AGE 62 62 62 62 62 62 62 62 62 62 62 62 62
SEX M M M M M M M M M M M M M
PLATELET COUNT 98000 92000 94000 99000 90000 84000 85000 100000 91000 86000 92000 95000 98000
HB 7.1 6.9 6.4 6.7 6.5 7 6.3 6.2 6.7 5.9 6 5.6 5.8
PCV 24 23 18 26 26 25 18 20 24 21 19 27 25
TC (in thousands) 15.4 10.4 10.6 7.9 8.0 7.9 9.2 7.7 7.4 10.0 7.1 8.1 10.9
UREA 61 49 51 46 48 45 47 44 46 41 50 49 53
CREATINE 0.9 1.2 1.2 1.0 1.3 1.5 1.2 1.1 1.0 1.5 1.4 1.0 1.2
SODIUM 146 133 131 128 127 135 136 132 135 135 136 130 131
POTASSIUM 3.1 2.6 4.4 2.7 3.0 3.1 4.1 2.7 3.8 3.0 3.2 4.7 2.4
T.BILIRUBIN 10.1 13.8 14.8 12.7 13.1 7.4 6.1 5.1 7.8 2.7 3.0 3.2 3.5
D.BILIRUBIN 4.4 3.9 3.1 2.5 3.1 3.0 2.7 3.6 2.6 1.8 2.3 2.2 2.2
OT 409 458 312 403 332 196 188 194 194 70 52 63 95
PT 134 177 191 161 151 140 110 133 105 62 81 54 85
ALP 67 50 59 56 55 63 64 53 53 53 53 66 58
T.PROTEIN 5.7 4.9 5.0 5.6 4.8 5.3 5.1 5.2 5.0 4.8 4.9 5.2 5.2
S.ALBUMIN 2.6 2.4 2.7 2.7 2.4 2.5 2.5 2.6 2.7 2.4 2.4 2.5 2.8
INR 3.5 4.1 3.4 2.9 1.8 1.9 1.7 2.1 1.9 1.6 1.6 2.0 2.2
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 3 EV GRADE 3 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 45 45 45 45 45 45 45 45 45 45 45 45 45
SEX M M M M M M M M M M M M M
PLATELET COUNT 80000 80000 82000 97000 78000 72000 73000 88600 79600 74600 80600 83600 86000
HB 8.2 8.1 7.6 7.9 7.7 8.2 7.5 7.4 7.9 7.1 7.2 6.8 7
PCV 25 18 19 27 26 18 19 25 18 23 19 23 20
TC (in thousands) 11.8 9.5 10.5 4.8 5.6 10.0 5.9 7.0 7.2 8.4 5.4 9.7 7.2
UREA 46 48 46 49 45 39 46 44 36 55 39 32 39
CREATINE 0.8 1.2 1.2 1.3 1.1 1.1 1.1 1.1 1.0 1.2 1.4 1.4 1.2
SODIUM 143 128 136 128 133 136 129 136 130 128 134 127 130
POTASSIUM 4.4 2.5 3.4 4.5 4.3 3.8 3.4 3.8 4.5 4.2 3.6 2.7 4.1
T.BILIRUBIN 12.9 13.0 12.6 13.1 11.3 16.1 5.6 6.3 6.2 3.6 4.4 3.1 3.1
D.BILIRUBIN 4.9 3.1 2.6 2.6 3.6 5.5 3.6 3.9 2.3 2.2 3.3 2.0 1.6
OT 389 444 392 366 455 178 182 176 181 63 71 68 53
PT 126 191 164 177 192 128 113 150 150 96 82 96 58
ALP 57 69 60 61 59 58 58 58 62 53 55 66 50
T.PROTEIN 5.5 5.3 4.8 5.1 5.2 5.0 5.1 5.5 5.0 5.4 5.0 5.2 5.3
S.ALBUMIN 2.8 2.5 2.4 2.8 2.4 2.8 2.6 2.6 2.4 2.8 2.7 2.7 2.7
INR 3.7 4.0 3.1 1.6 4.4 1.8 2.1 2.5 1.7 2.4 1.6 2.3 1.5
SUBJECT 24
SUBJECT 25
SUBJECT 26
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 63 63 63 63 63 63 63 63 63 63 63 63 63
SEX M M M M M M M M M M M M M
PLATELET COUNT 46000 44000 46000 51000 42000 36000 37000 52000 43000 38000 44000 47000 50000
HB 9.2 9.2 8.7 9 8.8 9.3 8.6 8.5 9 8.2 8.3 7.9 8.1
PCV 26 18 21 23 23 23 27 23 19 18 22 18 24
TC (in thousands) 18.9 7.9 8.4 9.4 9.7 8.4 5.7 6.4 8.1 10.4 8.9 5.6 9.5
UREA 62 36 30 32 48 32 50 35 54 43 47 44 44
CREATINE 1.3 1.1 1.4 1.4 1.1 1.5 1.3 1.5 1.4 1.3 1.1 1.3 1.1
SODIUM 126 133 132 134 127 135 134 131 136 133 129 136 133
POTASSIUM 4.1 4.5 2.5 4.1 3.1 3.3 4.6 2.6 3.1 4.0 4.1 3.5 2.8
T.BILIRUBIN 10.1 11.5 13.7 13.3 12.6 14.4 5.1 7.8 6.1 4.5 2.8 3.9 3.7
D.BILIRUBIN 2.1 2.5 2.3 2.2 2.6 3.8 2.8 3.3 3.5 2.8 2.1 2.7 3.2
OT 369 254 304 442 414 182 179 180 189 54 57 71 58
PT 138 159 188 170 190 131 111 135 115 72 22 54 37
ALP 71 65 62 58 61 61 62 62 65 69 54 65 55
T.PROTEIN 5.6 5.4 4.9 5.0 4.8 4.8 5.4 5.2 5.2 5.4 5.6 5.3 4.9
S.ALBUMIN 2.6 2.6 2.7 2.5 2.4 2.4 2.7 2.7 2.4 2.6 2.5 2.8 2.6
INR 3.9 3.8 3.2 2.3 2.9 1.6 2.3 1.7 2.4 1.8 2.5 2.2 1.7
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 58 58 58 58 58 58 58 58 58 58 58 58 58
SEX M M M M M M M M M M M M M
PLATELET COUNT 101000 99000 101000 106000 97000 91000 92000 107000 98000 93000 99000 102000 105000
HB 9.3 8.9 8.4 8.7 8.5 9 8.3 8.2 8.7 7.9 8 7.6 7.8
PCV 32 28 21 26 24 20 23 22 18 27 22 23 25
TC (in thousands) 5.4 4.4 9.7 8.2 7.7 8.0 5.6 9.7 8.4 5.8 5.6 9.4 5.9
UREA 36 47 51 55 36 52 39 52 51 32 39 47 54
CREATINE 0.8 1.3 1.2 1.2 1.3 1.2 1.1 1.3 1.1 1.2 1.2 1.1 1.3
SODIUM 140 133 137 130 130 130 127 135 136 130 130 137 127
POTASSIUM 4 4.3 2.6 3.1 3.3 4.7 4.3 4.2 3.0 4.4 4.4 2.5 3.3
T.BILIRUBIN 10.5 13.1 12.3 13.3 13.0 6.4 6.2 5.8 8.0 3.3 2.0 2.8 7.1
D.BILIRUBIN 4.2 2.8 3.6 3.2 2.7 3.6 2.7 4.0 2.6 1.8 0.8 1.7 3.2
OT 412 385 426 311 332 185 178 199 175 63 60 244 67
PT 156 175 171 163 189 100 150 121 147 52 95 111 66
ALP 40 50 52 61 60 55 65 57 53 66 69 65 67
T.PROTEIN 5.8 5.3 5.1 5.0 5.0 4.9 4.8 5.2 5.1 5.1 5.3 5.2 5.0
S.ALBUMIN 2.5 2.5 2.4 2.5 2.7 2.5 2.6 2.4 2.7 2.6 2.5 2.5 2.7
INR 3.6 3.4 3.7 1.9 2.2 2.3 1.8 1.9 2.2 1.6 1.7 2.8 3.4
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 1 EV GRADE 1 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 53 53 53 53 53 53 53 53 53 53 53 53 53
SEX M M M M M M M M M M M M M
PLATELET COUNT 88000 85000 87000 92000 83000 77000 78000 93000 84000 79000 85000 88000 91000
HB 8.4 8.2 7.7 8 7.8 8.3 7.6 7.5 8 7.2 7.3 6.9 7.1
PCV 26 24 22 27 24 26 25 21 26 27 22 22 24
TC (in thousands) 11.5 9.5 4.2 7.9 8.1 10.6 8.4 11.0 5.1 10.1 7.7 10.9 10.9
UREA 55 45 52 30 38 50 47 38 51 33 33 51 38
CREATINE 0.9 1.3 1.3 1.0 1.4 1.4 1.2 1.5 1.4 1.4 1.0 1.0 1.4
SODIUM 144 131 132 127 132 134 135 137 133 136 133 132 128
POTASSIUM 4.6 4.8 3.2 4.7 2.8 2.6 3.4 3.2 4.7 3.9 2.7 2.4 3.4
T.BILIRUBIN 12.6 11.5 13.9 17.1 14.0 11.1 6.7 7.9 6.1 2.5 2.6 2.0 2.2
D.BILIRUBIN 3.8 3.4 2.4 3.0 2.8 4.2 3.0 3.3 2.2 1.1 1.0 1.0 0.4
OT 385 330 435 307 326 180 195 190 200 64 57 73 57
PT 142 184 200 163 177 102 129 125 148 83 53 51 60
ALP 52 50 50 65 69 67 51 66 50 66 61 51 59
SUBJECT 27
SUBJECT 28
SUBJECT 29
T.PROTEIN 5.5 5.3 5.0 5.1 5.6 5.4 5.2 5.4 4.8 5.5 4.9 5.1 4.9
S.ALBUMIN 2.6 2.6 2.6 2.7 2.5 2.6 2.6 2.7 2.7 2.8 2.5 2.6 2.8
INR 3.6 3.1 3.3 1.9 1.6 2.0 1.7 1.5 1.8 2.2 2.3 2.5 2.0
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 3 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 61 61 61 61 61 61 61 61 61 61 61 61 61
SEX M M M M M M M M M M M M M
PLATELET COUNT 66000 60000 62000 67000 58000 52000 53000 68000 59000 54000 60000 63000 66000
HB 7.3 7 6.5 6.8 6.6 7.1 6.4 6.3 6.8 6 6.1 5.7 5.9
PCV 25 24 26 25 26 26 26 20 20 25 27 22 24
TC (in thousands) 13.6 7.4 9.1 7.1 10.1 6.6 6.3 6.9 10.4 5.4 10.2 6.2 4.9
UREA 48 33 52 52 32 43 36 36 50 48 55 52 37
CREATINE 0.7 1.0 1.4 1.2 1.3 1.2 1.4 1.3 1.1 1.0 1.1 1.2 1.1
SODIUM 139 135 129 132 132 132 134 137 134 134 135 135 135
POTASSIUM 4.1 3.1 4.0 2.6 2.8 4.4 3.9 4.5 3.3 2.8 3.6 4.8 4.1
T.BILIRUBIN 12.7 13.7 11.7 12.1 13.1 16.6 5.5 7.9 7.9 2.7 2.1 2.8 2.3
D.BILIRUBIN 3.8 3.0 2.7 2.2 3.5 2.8 3.4 2.1 3.1 2.5 2.1 2.4 2.1
OT 246 201 362 380 468 187 188 188 199 61 64 69 73
PT 104 197 180 187 190 134 101 107 133 62 59 54 58
ALP 73 67 50 67 61 50 53 68 53 62 67 70 65
T.PROTEIN 5.9 5.3 4.9 5.2 5.6 5.3 5.6 5.4 5.1 5.5 5.3 5.1 5.2
S.ALBUMIN 2.7 2.6 2.5 2.7 2.5 2.5 2.7 2.7 2.7 2.6 2.5 2.4 2.7
INR 3.6 3.4 3.7 3.3 3.7 2.1 1.6 2.3 2.4 1.7 2.1 1.6 1.5
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 60 60 60 60 60 60 60 60 60 60 60 60 60
SEX M M M M M M M M M M M M M
PLATELET COUNT 68000 67000 64000 66000 69000 58000 55000 62000 66000 58000 59000 51000 57000
HB 6.6 6.3 5.8 6.1 5.9 6.4 5.7 5.6 6.1 5.3 5.4 5 5.2
PCV 21 20 18 19 21 25 27 25 18 18 23 24 18
TC (in thousands) 14.8 7.8 4.9 7.2 10.2 4.3 8.6 4.6 7.0 7.8 10.2 7.0 8.4
UREA 58 50 50 43 51 33 30 32 52 43 30 49 35
CREATINE 1.1 1.3 1.4 1.3 1.0 1.2 1.5 1.3 1.3 1.4 1.4 1.2 1.2
SODIUM 133 127 129 127 135 130 137 129 133 129 133 127 137
POTASSIUM 4.2 4.5 3.4 4.6 3.2 3.9 4.7 3.5 3.0 2.6 3.4 2.9 3.6
T.BILIRUBIN 13.6 11.4 12.4 13.8 11.3 14.1 5.6 5.8 7.5 3.5 2.3 3.7 2.9
D.BILIRUBIN 4.5 4.0 3.7 3.0 2.9 3.4 2.4 3.6 3.9 1.4 1.6 1.4 2.1
OT 377 226 278 258 354 183 192 187 186 50 68 51 60
PT 109 155 185 188 168 113 107 133 123 52 45 42 55
ALP 58 56 57 63 67 57 53 51 54 63 51 52 53
T.PROTEIN 5.8 5.6 5.2 5.4 4.8 5.4 4.9 5.1 5.6 5.4 5.2 4.8 5.3
S.ALBUMIN 2.6 2.4 2.4 2.5 2.5 2.7 2.8 2.4 2.4 2.5 2.4 2.5 2.4
INR 3.6 3.2 3.7 2.1 1.9 2.3 2.0 1.9 2.3 2.3 1.7 1.6 2.3
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 49 49 49 49 49 49 49 49 49 49 49 49 49
SEX M M M M M M M M M M M M M
PLATELET COUNT 88000 82000 84000 89000 80000 74000 75000 90000 81000 76000 82000 85000 88000
HB 7.9 7.7 7.2 7.5 7.3 7.8 7.1 7 7.5 6.7 6.8 6.4 6.6
PCV 23 24 22 19 24 25 27 27 23 24 25 18 24
TC (in thousands) 9.9 6.8 5.7 5.3 4.4 7.0 6.0 5.5 5.1 4.8 9.2 8.0 5.9
UREA 56 45 46 45 46 55 49 48 36 45 36 53 36
CREATINE 1.4 1.0 1.3 1.0 1.2 1.2 1.5 1.0 1.1 1.0 1.5 1.4 1.3
SODIUM 138 128 135 129 137 131 135 127 135 130 133 137 128
POTASSIUM 2.8 3.5 2.6 3.8 3.1 2.6 3.9 2.7 2.8 3.2 3.8 2.6 4.0
T.BILIRUBIN 12.6 13.3 13.0 12.2 12.5 12.9 8.8 6.1 6.9 3.7 3.0 3.6 2.1
D.BILIRUBIN 3.7 2.7 4.0 3.8 2.2 2.9 3.2 2.5 3.4 1.7 2.3 2.7 1.1
SUBJECT 30
SUBJECT 31
SUBJECT 32
OT 379 353 248 272 327 196 196 177 195 67 65 61 74
PT 201 193 191 167 183 135 139 132 102 67 64 60 50
ALP 53 70 61 61 63 57 62 60 50 61 67 64 54
T.PROTEIN 5.5 5.4 4.9 4.9 5.3 5.2 5.4 5.2 5.1 5.3 4.9 5.1 5.0
S.ALBUMIN 2.6 2.5 2.6 2.7 2.7 2.4 2.8 2.7 2.5 2.8 2.6 2.7 2.6
INR 3.1 4.0 3.9 1.7 1.8 2.3 1.6 1.9 2.0 2.5 2.4 2.1 2.1
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 57 57 57 57 57 57 57 57 57 57 57 57 57
SEX M M M M M M M M M M M M M
PLATELET COUNT 63000 62000 64000 69000 60000 54000 55000 70000 61000 56000 62000 65000 68000
HB 7.1 6.5 6 6.3 6.1 6.6 5.9 5.8 6.3 5.5 5.6 5.2 5.4
PCV 25 24 22 18 23 21 25 25 20 18 27 25 27
TC (in thousands) 11.4 5.1 9.7 9.1 5.1 6.1 8.3 10.5 7.1 10.1 4.1 4.4 5.1
UREA 44 33 43 34 38 55 43 45 42 45 38 30 34
CREATINE 1.2 1.1 1.2 1.2 1.2 1.2 1.1 1.1 1.2 1.2 1.2 1.1 1.0
SODIUM 126 129 127 136 137 131 135 133 129 130 131 136 136
POTASSIUM 3.4 3.3 3.0 3.9 4.2 3.8 4.3 3.6 3.1 4.0 2.6 3.5 4.6
T.BILIRUBIN 10.2 11.0 12.6 11.5 12.2 13.1 13.3 8.9 7.3 3.9 3.0 2.1 2.3
D.BILIRUBIN 2.1 3.0 3.4 3.8 3.8 3.9 2.6 3.2 4.0 2.8 2.1 1.1 1.4
OT 321 380 285 408 407 375 190 177 185 75 74 99 84
PT 100 180 160 184 175 122 133 130 141 85 54 89 74
ALP 64 62 63 52 66 64 70 51 50 70 56 64 66
T.PROTEIN 5.8 5.1 4.9 5.2 5.3 5.2 5.1 5.1 5.5 4.9 4.8 5.0 5.0
S.ALBUMIN 2.9 2.7 2.5 2.7 2.6 2.6 2.6 2.8 2.6 2.8 2.5 2.5 2.5
INR 4.1 3.8 4.2 2.5 2.3 2.2 2.4 2.0 2.3 1.8 1.8 2.0 1.5
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 39 39 39 39 39 39 39 39 39 39 39 39 39
SEX M M M M M M M M M M M M M
PLATELET COUNT 46000 47000 48000 54000 46000 59000 55000 54000 58000 51000 43000 50000 51000
HB 9.1 10 9.5 9.8 9.6 10.1 9.4 9.3 9.8 9 9.1 8.7 8.9
PCV 28 22 26 18 20 26 22 24 21 22 26 24 20
TC (in thousands) 17.1 10.8 9.6 6.6 4.0 6.4 6.3 4.4 4.0 11.0 6.2 4.2 5.7
UREA 54 41 55 38 52 32 38 48 53 32 42 43 46
CREATINE 1.2 1.2 1.3 1.3 1.2 1.4 1.1 1.1 1.3 1.2 1.1 1.4 1.3
SODIUM 131 128 137 128 127 127 132 136 137 130 134 132 137
POTASSIUM 4.6 4.8 3.8 3.0 2.9 3.4 4.1 4.8 4.2 2.6 3.6 3.0 2.6
T.BILIRUBIN 13.1 13.8 16.7 12.2 14.4 10.5 7.7 8.0 6.0 2.9 4.3 4.0 5.4
D.BILIRUBIN 2.9 3.3 4.9 2.4 3.5 5.1 2.1 3.5 3.0 2.8 3.0 3.2 3.4
OT 444 500 240 400 284 179 188 194 178 71 55 66 68
PT 195 161 179 161 183 142 124 107 140 100 72 79 64
ALP 56 58 65 65 57 60 60 60 53 50 56 51 57
T.PROTEIN 5.4 5.0 5.2 5.4 5.3 5.0 4.8 5.5 4.9 5.3 5.1 5.4 5.0
S.ALBUMIN 2.5 2.8 2.6 2.7 2.8 2.7 2.7 2.6 2.8 2.7 2.6 2.5 2.8
INR 4.7 3.8 3.3 2.4 2.2 1.9 1.7 1.8 2.0 2.0 1.7 1.7 2.0
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 3 EV GRADE 3 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 50 50 50 50 50 50 50 50 50 50 50 50 50
SEX M M M M M M M M M M M M M
PLATELET COUNT 103000 104000 102000 107000 98000 92000 93000 108000 99000 94000 100000 103000 106000
HB 9.4 9.2 8.7 9 8.8 9.3 8.6 8.5 9 8.2 8.3 7.9 8.1
PCV 26 24 21 19 24 22 21 19 23 23 23 20 19
TC (in thousands) 8.8 5.9 9.6 8.8 10.7 9.5 5.9 5.0 4.6 9.4 6.4 10.9 10.1
UREA 44 30 54 35 42 54 31 47 55 43 31 44 43
CREATINE 1 1.3 1.2 1.1 1.4 1.3 1.2 1.5 1.5 1.3 1.2 1.5 1.2
SODIUM 140 130 127 128 127 137 131 135 137 130 127 127 136
SUBJECT 33
SUBJECT 34
POTASSIUM 4.5 3.0 4.5 4.4 4.4 3.4 2.7 3.0 3.4 3.4 3.0 4.8 3.3
T.BILIRUBIN 10.8 11.4 13.3 14.4 12.1 15.7 11.9 7.8 7.4 3.3 2.1 2.2 2.3
D.BILIRUBIN 3.2 3.3 3.0 4.1 3.8 4.7 3.3 3.8 3.7 2.5 1.1 0.5 0.5
OT 380 426 431 228 435 181 188 196 193 66 52 150 152
PT 147 157 157 199 174 145 145 111 150 56 58 62 91
ALP 66 69 64 70 55 51 64 58 51 68 50 68 53
T.PROTEIN 5.7 5.1 5.6 5.4 5.2 5.0 5.2 5.4 5.5 5.3 5.3 5.2 4.9
S.ALBUMIN 2.5 2.4 2.4 2.7 2.7 2.7 2.5 2.7 2.7 2.6 2.7 2.5 2.4
INR 4 3.8 3.4 1.7 1.6 1.7 1.6 1.5 1.8 2.1 2.4 2.4 2.4
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 45 45 45 45 45 45 45 45 45 45 45 45 45
SEX M M M M M M M M M M M M M
PLATELET COUNT 55000 54000 56000 61000 52000 46000 47000 62000 53000 48000 54000 57000 60000
HB 10.3 10.9 10.4 10.7 10.5 11 10.3 10.2 10.7 9.9 10 9.6 9.8
PCV 28 26 20 18 18 26 26 19 27 20 27 23 20
TC (in thousands) 9.5 7.9 9.8 10.6 4.5 9.7 6.0 6.4 4.8 4.4 6.3 7.7 7.7
UREA 41 35 55 51 48 35 46 32 30 43 50 44 38
CREATINE 0.8 1.4 1.3 1.1 1.1 1.1 1.3 1.3 1.4 1.1 1.1 1.2 1.2
SODIUM 143 132 128 133 132 136 131 134 127 130 132 128 128
POTASSIUM 4.2 2.7 3.5 4.1 4.2 4.6 2.8 4.1 2.5 2.4 3.3 2.4 2.6
T.BILIRUBIN 10.6 13.6 13.1 11.5 13.7 9.3 7.1 6.9 5.8 3.2 2.7 3.2 2.8
D.BILIRUBIN 3.6 3.3 3.3 2.3 3.0 2.7 2.8 3.9 3.0 2.5 1.9 2.2 1.6
OT 363 265 293 349 364 196 182 185 177 117 113 74 61
PT 114 188 165 174 189 108 145 133 115 79 88 68 58
ALP 64 66 66 65 53 56 66 51 62 62 61 55 60
T.PROTEIN 5.7 4.9 5.0 5.5 5.1 5.6 5.0 5.3 5.0 5.2 4.9 4.9 5.1
S.ALBUMIN 2.6 2.4 2.5 2.5 2.7 2.5 2.6 2.6 2.8 2.5 2.8 2.6 2.6
INR 3.8 3.6 3.9 1.7 2.1 1.5 2.1 1.7 2.1 2.4 2.4 2.4 1.9
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 55 55 55 55 55 55 55 55 55 55 55 55 55
SEX M M M M M M M M M M M M M
PLATELET COUNT 77000 74000 73000 75000 63000 68000 67000 74000 62000 66000 66000 65000 64000
HB 6.1 5.9 5.4 5.7 5.5 6 5.3 5.2 5.7 4.9 5 4.6 4.8
PCV 25 23 20 18 27 27 20 23 21 24 25 21 18
TC (in thousands) 9.1 5.2 6.8 6.5 5.5 10.8 5.7 9.1 4.6 8.1 7.3 7.6 4.1
UREA 67 55 30 36 53 33 36 54 31 48 30 37 49
CREATINE 1.2 1.0 1.3 1.1 1.3 1.3 1.1 1.1 1.2 1.3 1.2 1.1 1.2
SODIUM 137 128 134 130 131 132 135 127 129 137 131 134 131
POTASSIUM 3.2 4.7 4.2 4.5 4.8 2.6 4.4 3.1 3.7 3.9 4.5 3.8 3.6
T.BILIRUBIN 11.6 13.3 12.8 15.2 16.7 12.8 7.7 7.4 5.3 5.5 5.5 4.2 4.9
D.BILIRUBIN 3.7 3.3 2.2 3.7 3.8 2.1 3.3 2.7 3.2 4.0 3.9 2.6 3.2
OT 395 212 427 335 424 200 181 185 188 56 63 75 50
PT 140 185 191 190 198 118 104 126 136 79 56 73 76
ALP 60 61 50 59 52 57 53 68 57 69 57 50 66
T.PROTEIN 5.2 4.9 5.0 4.9 5.1 5.6 4.9 4.9 5.0 5.1 5.0 5.4 4.9
S.ALBUMIN 2.6 2.6 2.4 2.5 2.7 2.6 2.5 2.4 2.6 2.4 2.6 2.7 2.7
INR 3.6 3.5 3.7 1.7 2.4 1.9 1.9 2.0 2.4 2.2 1.6 2.2 1.6
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 53 53 53 53 53 53 53 53 53 53 53 53 53
SEX M M M M M M M M M M M M M
PLATELET COUNT 95000 90000 92000 97000 88000 82000 83000 98000 89000 84000 90000 93000 96000
HB 6.6 6.3 5.8 6.1 5.9 6.4 5.7 5.6 6.1 5.3 5.4 5 5.2
PCV 20 23 20 18 23 25 27 27 21 22 22 18 25
TC (in thousands) 16.4 9.2 6.9 10.2 6.7 6.6 6.7 5.4 5.2 4.5 8.9 10.8 7.0
SUBJECT 35
SUBJECT 36
SUBJECT 37
UREA 34 31 32 34 39 49 50 53 44 47 33 30 35
CREATINE 0.8 1.2 1.0 1.1 1.1 1.3 1.0 1.3 1.1 1.2 1.3 1.2 1.3
SODIUM 142 130 135 131 130 129 135 136 128 135 136 127 134
POTASSIUM 2.7 2.5 4.0 4.7 3.5 3.7 4.4 4.2 3.5 3.2 2.4 3.9 3.7
T.BILIRUBIN 14.1 12.0 13.5 11.3 12.7 11.1 8.4 6.3 7.3 5.1 4.5 5.4 4.5
D.BILIRUBIN 4.7 2.4 2.8 2.5 2.5 3.5 2.9 2.3 2.0 3.6 2.7 3.6 3.7
OT 411 359 310 491 249 192 191 191 185 60 74 83 96
PT 238 152 198 153 176 140 111 139 130 49 55 66 94
ALP 63 64 68 60 58 52 58 64 52 61 53 59 68
T.PROTEIN 5.4 5.1 5.4 5.3 5.4 5.3 5.5 5.0 5.4 5.5 5.5 5.1 5.4
S.ALBUMIN 2.6 2.6 2.5 2.5 2.6 2.6 2.6 2.4 2.6 2.4 2.4 2.4 2.6
INR 4.6 4.0 3.9 1.8 2.3 2.0 1.7 2.3 2.2 1.6 2.2 2.0 2.1
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 68 68 68 68 68 68 68 68 68 68 68 68 68
SEX M M M M M M M M M M M M M
PLATELET COUNT 55000 51000 53000 58000 49000 43000 44000 59000 50000 45000 51000 54000 57000
HB 6.2 6.5 6 6.3 6.1 6.6 5.9 5.8 6.3 5.5 5.6 5.2 5.4
PCV 21 24 22 21 21 18 18 19 26 22 26 22 27
TC (in thousands) 7.3 5.8 7.5 8.0 4.2 10.0 6.8 5.8 6.6 10.1 5.1 6.6 5.0
UREA 58 40 44 37 33 49 37 34 47 51 52 40 53
CREATINE 1.1 1.4 1.4 1.4 1.5 1.2 1.3 1.5 1.4 1.4 1.0 1.5 1.2
SODIUM 128 131 129 136 136 130 132 137 129 129 137 136 133
POTASSIUM 3.2 3.5 2.7 4.0 4.2 4.8 3.3 3.3 3.8 2.6 4.7 3.1 3.1
T.BILIRUBIN 12.9 11.9 12.4 13.1 15.1 11.1 7.2 7.7 7.0 5.0 5.2 5.6 5.1
D.BILIRUBIN 5.3 2.4 3.9 3.0 3.1 2.2 4.0 2.9 3.6 3.9 3.9 3.1 3.0
OT 304 262 285 471 423 194 199 198 193 68 57 75 62
PT 191 166 157 188 157 120 135 106 149 41 52 62 82
ALP 74 51 52 50 58 64 50 61 52 66 56 63 55
T.PROTEIN 5.6 5.2 5.3 5.1 5.0 5.1 5.3 5.6 5.4 5.4 4.8 5.3 5.1
S.ALBUMIN 2.6 2.5 2.7 2.4 2.7 2.5 2.8 2.5 2.6 2.6 2.5 2.5 2.4
INR 3.9 3.2 3.7 2.1 1.5 2.3 1.6 1.7 1.6 1.9 2.2 1.7 2.5
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
CAUSE OF HEPATITIS ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKEALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE ALCOHOL INTAKE
AGE 44 44 44 44 44 44 44 44 44 44 44 44 44
SEX M M M M M M M M M M M M M
PLATELET COUNT 61000 58000 60000 62000 61000 61000 58000 52000 57000 58000 61000 64000 63000
HB 6.9 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8 6.8
PCV 26 25 22 22 27 26 24 23 18 25 19 21 27
TC (in thousands) 10.9 7.5 5.6 8.4 8.8 10.2 8.2 10.9 8.0 5.0 6.5 9.7 9.0
UREA 34 37 37 42 30 32 35 32 41 51 32 33 38
CREATINE 0.7 1.4 1.4 1.0 1.3 1.4 1.2 1.1 1.2 1.2 1.1 1.3 1.2
SODIUM 125 137 132 127 137 134 131 130 131 130 129 128 129
POTASSIUM 4.2 3.3 4.4 3.3 3.2 4.8 3.3 2.7 3.4 2.7 4.3 3.4 3.3
T.BILIRUBIN 12.1 11.4 12.4 13.4 12.9 10.2 8.8 6.5 6.9 3.7 2.6 3.3 3.5
D.BILIRUBIN 5.1 3.8 2.2 3.7 3.0 2.5 3.2 2.1 3.7 2.0 2.0 2.4 2.3
OT 450 470 340 383 312 188 175 176 199 142 135 75 82
PT 155 181 171 176 162 100 107 141 131 83 77 52 63
ALP 60 55 60 65 69 66 69 60 69 68 66 51 61
T.PROTEIN 5.4 4.8 5.2 5.4 4.8 5.3 4.9 5.0 5.0 5.3 5.0 5.1 4.8
S.ALBUMIN 2.5 2.5 2.5 2.5 2.7 2.6 2.7 2.6 2.7 2.4 2.4 2.5 2.7
INR 4.4 3.9 3.8 1.8 2.2 1.8 2.4 2.1 2.5 1.7 2.0 2.1 2.5
VIRAL HEPATITIS MARKERS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE
GLYCAEMIC PROFILE NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL
ULTRA SOUND ABDOMEN CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD CLD
UPPER GI ENDOSCOPY GRADE 2 EV GRADE 2 EV
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